CN115232815A - Gene editing system for constructing MIP gene mutation cataract disease model pig nuclear transplantation donor cell and application thereof - Google Patents

Gene editing system for constructing MIP gene mutation cataract disease model pig nuclear transplantation donor cell and application thereof Download PDF

Info

Publication number
CN115232815A
CN115232815A CN202110923993.XA CN202110923993A CN115232815A CN 115232815 A CN115232815 A CN 115232815A CN 202110923993 A CN202110923993 A CN 202110923993A CN 115232815 A CN115232815 A CN 115232815A
Authority
CN
China
Prior art keywords
mip
protein
cataract
leu
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202110923993.XA
Other languages
Chinese (zh)
Inventor
牛冬
汪滔
陶裴裴
刘璐
曾为俊
王磊
程锐
赵泽英
马翔
黄彩云
段星
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanjing Qizhen Genetic Engineering Co Ltd
Original Assignee
Nanjing Qizhen Genetic Engineering Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanjing Qizhen Genetic Engineering Co Ltd filed Critical Nanjing Qizhen Genetic Engineering Co Ltd
Priority to CN202110923993.XA priority Critical patent/CN115232815A/en
Publication of CN115232815A publication Critical patent/CN115232815A/en
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0273—Cloned vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/873—Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos
    • C12N15/877—Techniques for producing new mammalian cloned embryos
    • C12N15/8778—Swine embryos
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0656—Adult fibroblasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/108—Swine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C12N2503/02—Drug screening
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Rheumatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Environmental Sciences (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)

Abstract

The invention discloses a gene editing system for constructing MIP gene mutation cataract disease model pig nuclear transplantation donor cells and application thereof. The present invention provides SEQ ID NO:18, MIP-gRNA2 of SEQ ID NO:19, MIP-gRNA3 and NCN protein in the preparation of a kit. The invention also provides a method for preparing recombinant cells, which comprises the following steps: and (3) co-transfecting the MIP-gRNA2, the MIP-gRNA3 and the NCN protein into a pig cell to obtain a recombinant cell. The recombinant cell is a recombinant cell with MIP gene mutation. The use of any one of the above kits is: preparing a recombinant cell; preparing a cataract model pig; preparing a cataract cell model or a cataract tissue model or a cataract organ model. The invention has great application value for researching and developing cataract drugs and revealing pathogenesis of cataract.

Description

Gene editing system for constructing MIP gene mutation cataract disease model pig nuclear transplantation donor cell and application thereof
Technical Field
The invention belongs to the technical field of biology, particularly belongs to the technical field of gene editing, and more particularly relates to a gene editing system for constructing cataract disease model pig nuclear transplantation donor cells with MIP gene mutation and application thereof.
Background
Congenital Cataract (Congenital Cataract) refers to a Cataract caused by Congenital genetic or developmental disorder that is present at birth or develops within the last year of birth, and has significant genetic heterogeneity. The incidence of congenital cataract is 0.01% -0.06% worldwide. The congenital cataract is a common eye disease of children, and according to the report of WHO, the congenital cataract accounts for about 10 to 38 percent of the worldwide cases of blindness of children due to various reasons every year.
There are three different genetic patterns of congenital cataracts: autosomal dominant inheritance, autosomal recessive inheritance and sex chromosome linkage inheritance, wherein the autosomal dominant inheritance is the most common inheritance mode of congenital cataract. It is now reported that the genes associated with congenital cataract are classified into 4 types: lens proteins, membrane proteins, cytoskeletal proteins, growth and development regulatory factors.
The lens, a non-vascular tissue, is completely dependent on lens epithelium to maintain extracellular normal ionic state and redox state, and membrane proteins on lens cell surface play an important role in maintaining cell metabolism and ion exchange, etc. to ensure normal transmission of intercellular signal molecules and maintain transparency of the lens.
MIP (major intrinsic protein of lens fiber) is an intrinsic membrane protein, accounting for 80% of the total membrane protein of lens fiber cells, and MIP monomers are combined into tetramers in the cell membrane to form water channels, selectively transporting water molecules through the cell membrane, and maintaining the lens transparent mainly by reducing the gaps among the lens fiber cells. It has been shown that mutations in the MIP gene in humans and mice lead to genetic cataracts, and that deletion of this gene in mouse studies results in insufficient suture formation required for maintenance of the fibrous structure of the lens, which in turn leads to interference with the accommodation and focusing properties of the lens.
So far, no medicine for treating cataract exists in the world, and some medicines only play a role in slowing down the development of cataract but cannot radically reverse the disease. Therefore, the research on the mechanism of occurrence and development of cataract caused by MIP gene mutation and the development of corresponding drugs are urgent, and the research needs to be carried out on the basis of animal models. The current common animal model is a mouse model, however, the mouse is different from the human body in the aspects of body type, organ size, physiology, pathology and the like, and the normal physiological and pathological states of the human body cannot be simulated really. The pig as a large animal has similar body size and physiological function to human, is easy to breed and feed in large scale, has low requirements on ethics, animal protection and the like, and is an ideal human disease model animal.
Gene editing is a biotechnology that has been greatly developed in recent years, and includes editing technologies from homologous recombination-based gene editing to nuclease-based ZFNs, TALENs, CRISPR/Cas9, and the like, wherein CRISPR/Cas9 technology is currently the most advanced gene editing technology. Currently, gene editing techniques are increasingly applied to the production of animal models.
Disclosure of Invention
The invention aims to provide a gene editing system for constructing a cataract disease model pig nuclear transplantation donor cell with MIP gene mutation and application thereof.
The invention provides application of MIP-gRNA2, MIP-gRNA3 and NCN proteins in preparation of a kit.
The invention also provides application of MIP-gRNA2, MIP-gRNA3 and PRONCN proteins in preparation of the kit.
The invention also provides application of MIP-gRNA2, MIP-gRNA3 and the idiosyncratic particles in preparation of the kit.
The invention also provides a method for preparing recombinant cells, which comprises the following steps: and (3) co-transfecting the MIP-gRNA2, the MIP-gRNA3 and the NCN protein into a pig cell to obtain a recombinant cell.
The recombinant cell is a recombinant cell with MIP gene mutation.
The mutation is a deletion and/or insertion and/or substitution of one or more nucleotides.
The recombinant cell may be any of the heterozygote type unicellular clones, biallelic different mutant unicellular clones or biallelic same mutant unicellular clones in table 1.
The invention provides a kit, which comprises MIP-gRNA2, MIP-gRNA3 and NCN protein.
The invention provides a kit, which comprises MIP-gRNA2, MIP-gRNA3 and PRONCN protein.
The invention provides a kit, which comprises MIP-gRNA2, MIP-gRNA3 and specific plasmids.
Any of the kits above further comprising porcine cells.
The use of any one of the above kits is (a) or (b) or (c): (a) preparing a recombinant cell; (b) preparing cataract model pig; (c) Preparing a cataract cell model or a cataract tissue model or a cataract organ model.
The co-transfection is specifically a shock transfection.
The parameter settings of the electroporation transfection can be specifically as follows: 1450V, 10ms, 3pulse.
The co-transfection may be specifically carried out using a mammalian nuclear transfection kit (Neon kit, thermofeisher) and a Neon TM transfection system electrotransfer apparatus.
The proportion of MIP-gRNA2, MIP-gRNA3 and NCN protein is as follows in sequence: 0.8-1.2 μ g MIP-gRNA2:0.8-1.2 μ g mip-gRNA3: 3-5. Mu.g NCN protein.
The proportion of MIP-gRNA2, MIP-gRNA3 and NCN protein is as follows in sequence: 1 μ g MIP-gRNA2:1 μ g MIP-gRNA3: mu.g NCN protein.
The proportions of the pig cells, the MIP-gRNA2, the MIP-gRNA3 and the NCN protein are as follows in sequence: 10 ten thousand porcine cells: 0.8-1.2 μ g mip-gRNA2:0.8-1.2 μ g MIP-gRNA3: 3-5. Mu.g NCN protein.
The proportions of the pig cells, the MIP-gRNA2, the MIP-gRNA3 and the NCN protein are as follows in sequence: 10 ten thousand porcine cells: 1 μ g mip-gRNA2:1 μ g MIP-gRNA3: mu.g NCN protein.
Any one of the MIP-gRNA2 is sgRNA, and a target sequence binding region thereof is as set forth in SEQ ID NO:18 from nucleotide 3 to nucleotide 22.
Specifically, the MIP-gRNA2 is shown in SEQ ID NO:18, respectively.
Specifically, the MIP-gRNA2 is shown as SEQ ID NO:11, respectively.
Any one of the MIP-gRNA3 is sgRNA, and a target sequence binding region thereof is as shown in SEQ ID NO:19 at nucleotides 3 to 22.
Specifically, the MIP-gRNA3 is shown in SEQ ID NO:19, respectively.
Specifically, the MIP-gRNA3 is shown as SEQ ID NO: shown at 12.
Any of the NCN proteins described above is a Cas9 protein or a fusion protein with a Cas9 protein.
Specifically, the NCN protein is shown as SEQ ID NO:3, respectively.
Any one of the above porcine cells is a porcine fibroblast.
Any of the above porcine cells are porcine primary fibroblasts.
The preparation method of the NCN protein comprises the following steps:
(1) Introducing the plasmid pKG-GE4 into escherichia coli BL21 (DE 3) to obtain a recombinant strain;
(2) Culturing the recombinant bacteria by adopting a liquid culture medium at 30 ℃, then adding IPTG (isopropyl-beta-D-thiogalactoside) and carrying out induced culture at 25 ℃, and then collecting bacteria;
(3) Crushing the collected thalli, and collecting a crude protein solution;
(4) Purification of the crude protein solution with His by affinity chromatography 6 A fusion protein of the tag;
(5) By means of a compound having His 6 Tagged enterokinase cleavage with His 6 The tagged fusion protein was then removed with His using Ni-NTA resin 6 A tagged protein, resulting in a purified NCN protein;
plasmid pKG-GE4 has the sequence shown in SEQ ID NO:1, nucleotide 5209-9852.
The preparation method of the NCN protein specifically comprises the following steps:
(1) The plasmid pKG-GE4 was introduced into E.coli BL21 (DE 3) to obtain a recombinant strain.
(2) Inoculating the recombinant bacteria obtained in the step (1) to a liquid LB culture medium containing ampicillin, and carrying out shake culture;
(3) Inoculating the bacterial liquid obtained in the step (2) to a liquid LB culture medium, and carrying out shaking culture at 30 ℃ and 230rpm until the bacterial liquid is OD 600nm The value =1.0, then IPTG was added to make the concentration in the system 0.5mM, followed by shaking culture at 230rpm at 25 ℃ for 12 hours, and then the cells were collected by centrifugation;
(4) Taking the thalli obtained in the step (3), and washing the thalli with a PBS (phosphate buffer solution);
(5) Adding the crude extraction buffer solution into the thalli obtained in the step (4), suspending the thalli, then crushing the thalli, then centrifugally collecting supernate, filtering by adopting a filter membrane with the aperture of 0.22 mu m, and collecting filtrate;
(6) Purifying the filtrate obtained in step (5) to give a purified product having His by affinity chromatography 6 A fusion protein of the tag (the fusion protein shown in SEQ ID NO: 2);
(7) Taking the post-column solution collected in the step (6), concentrating by using an ultrafiltration tube, and then diluting with 25mM Tris-HCl (pH8.0);
(8) Will have His 6 Adding the labeled recombinant bovine enterokinase into the solution obtained in the step (7), and performing enzyme digestion;
(9) Mixing the solution obtained in the step (8) with Ni-NTA resin, incubating, centrifuging and collecting supernatant;
(10) And (4) concentrating the supernatant obtained in the step (9) by using an ultrafiltration tube, and then adding the concentrated supernatant into an enzyme stock solution to obtain the NCN protein solution.
Purifying the filtrate obtained in step (5) by affinity chromatography to obtain a purified product having His 6 The specific method of the labeled fusion protein is as follows:
firstly, balancing a Ni-NTA agarose column by using a balancing solution with 5 column volumes (the flow rate is 1 ml/min); then, 50ml of the filtrate obtained in the step (5) is loaded (the flow rate is 0.5-1 ml/min); the column was then washed with 5 column volumes of equilibration solution (flow rate 1 ml/min); the column was then washed with 5 column volumes of buffer (flow rate 1 ml/min) to remove contaminating proteins; then eluting with 10 column volumes of eluent at flow rate of 0.5-1ml/min, and collecting the solution (90-100 ml) after passing through the column.
Any one of the PRONCN proteins sequentially comprises the following elements from upstream to downstream: signal peptide, molecular chaperone protein, protein tag, protease cleavage site, nuclear localization signal, cas9 protein, nuclear localization signal.
The signal peptide has the function of promoting protein secretion expression. The signal peptide may be selected from the group consisting of the escherichia coli alkaline phosphatase (phoA) signal peptide, the staphylococcus aureus protein a signal peptide, the escherichia coli outer membrane protein (ompa) signal peptide or the signal peptide of any other prokaryotic gene, preferably the alkaline phosphatase signal peptide (phoA signal peptide). The signal peptide of alkaline phosphatase is used to guide the secretory expression of the target protein into the bacterial periplasm cavity so as to be separated from the protein in the bacterial cell, and the target protein secreted into the bacterial periplasm cavity is soluble expression and can be cleaved by the signal peptidase in the bacterial periplasm cavity.
The chaperone protein functions to increase the solubility of the protein. The chaperone may be any protein that helps to form disulfide bonds, preferably a thioredoxin (TrxA protein). The thioredoxin can be used as a molecular chaperone to help a co-expressed target protein (such as a Cas9 protein) to form a disulfide bond, so that the stability and the folding correctness of the protein are improved, and the solubility and the activity of the target protein are increased.
The protein tag functions for protein purification. The Tag can be His Tag (His-Tag, his) 6 Protein tag), GST tag, flag tag, HA tag, c-Myc tag, or any other protein tag, more preferably His tag. The His tag can be combined with a Ni column, and the target protein can be purified by one-step Ni column affinity chromatography, so that the purification process of the target protein can be greatly simplified.
The protease cleavage site functions to cleave non-functional segments after purification to release the native form of the Cas9 protein. The protease may be selected from Enterokinase (Enterokinase), factor Xa (Factor Xa), thrombin (thrombobin), TEV protease (TEV protease), HRV 3C protease (HRV 3C protease), WELQut protease or any other endoprotease, further preferably Enterokinase. EK is an enterokinase enzyme cutting site, and is convenient for cutting the fused TrxA-His section by using enterokinase to obtain the Cas9 protein in a natural form. After the commodity enterokinase enzyme digestion fusion protein with the His label is used, the TrxA-His section and the enterokinase with the His label can be removed through once affinity chromatography to obtain the Cas9 protein in a natural form, and the damage and the loss of the target protein caused by repeated purification and dialysis are avoided.
The nuclear localization signal may be any nuclear localization signal, preferably an SV40 nuclear localization signal and/or a nucleocapsin nuclear localization signal. NLS is a nuclear localization signal, and NLS sites are respectively designed at the N end and the C end of Cas9, so that Cas9 can more effectively enter a cell nucleus for gene editing.
The Cas9 protein may be saCas9 or spCas9, preferably a spCas9 protein.
The PRONCN protein is specifically shown as SEQ ID NO:2, respectively.
Any one of the above specific plasmids sequentially comprises the following elements from upstream to downstream: promoter, operator, ribosome binding site, PRONCN protein coding gene and terminator.
The promoter may specifically be a T7 promoter. The T7 promoter is a prokaryotic expression strong promoter and can efficiently drive the expression of exogenous genes.
The operon may specifically be a Lac operon. The Lac operon is a regulatory element for lactose induced expression, and after bacteria grow to a certain amount, IPTG is used for inducing the expression of the target protein at low temperature, so that the influence of the premature expression of the target protein on the growth of host bacteria can be avoided, and the solubility of the expressed target protein is also obviously improved by the induced expression at low temperature.
The ribosome binding site is a ribosome binding site for translation of a protein, and is essential for translation of a protein.
The terminator may specifically be a T7 terminator. The T7 terminator can effectively terminate gene transcription at the end of the target gene, and prevent other downstream sequences except the target gene from being transcribed and translated.
For the codon of the spCas9 protein, the codon is optimized, so that the codon preference of the escherichia coli high-efficiency expression strain E.coli BL21 (DE 3) selected by the application is completely adapted, and the expression level of the Cas9 protein is improved.
The T7 promoter is shown as SEQ ID NO:1 from nucleotide 5121 to nucleotide 5139.
The Lac operon is shown as SEQ ID NO:1 from nucleotide 5140 to nucleotide 5164.
The ribosome binding site is shown as SEQ ID NO:1, nucleotides 5178 to 5201.
The coding sequence of the alkaline phosphatase signal peptide is shown as SEQ ID NO:1, nucleotide 5209-5271.
The coding sequence of the TrxA protein is shown as SEQ ID NO:1, nucleotides 5272-5598.
The coding sequence of His-Tag is shown as SEQ ID NO:1, nucleotides 5620-5637.
The coding sequence of the enterokinase enzyme cutting site is shown as SEQ ID NO:1 from nucleotide 5638 to nucleotide 5652.
The coding sequence of the nuclear localization signal is shown as SEQ ID NO:1 from nucleotide 5656 to nucleotide 5670.
The coding sequence of the spCas9 protein is shown in SEQ ID NO:1, nucleotides 5701-9801.
The coding sequence of the nuclear localization signal is shown as SEQ ID NO:1 from nucleotide 9802 to nucleotide 9849.
The T7 terminator is shown as SEQ ID NO: nucleotides 9902-9949 of 1.
Specifically, the specific plasmid is plasmid pKG-GE4.
Plasmid pKG-GE4 has the sequence shown in SEQ ID NO:1, nucleotides 5121-9949.
Specifically, any one of the plasmids pKG-GE4 is shown as SEQ ID NO:1 is shown.
The invention also protects the recombinant cell prepared by any one of the methods.
The invention also protects the application of the recombinant cell in preparing cataract model pigs.
The recombinant cell is taken as a nuclear transplantation donor cell to carry out somatic cell cloning, so that a cloned pig, namely the cataract model pig can be obtained.
The invention also protects a pig tissue of a model pig prepared by using the recombinant cell, namely a cataract tissue model.
The invention also protects a pig organ of a model pig prepared by the recombinant cell, namely a cataract organ model.
The invention also protects the pig cell of the model pig prepared by the recombinant cell, namely a cataract cell model.
The invention also protects the application of the recombinant cell, the cataract tissue model, the cataract organ model, the cataract cell model or the cataract model pig, which is (d 1) or (d 2) or (d 3) or (d 4) as follows:
(d1) Screening the medicine for treating cataract;
(d2) Evaluating the drug effect of the cataract drug;
(d3) Evaluating the curative effect of gene therapy and/or cell therapy of cataract;
(d4) The pathogenesis of cataracts is studied.
Any one of the pigs may be a Yuanjiang fragrant pig.
Any of the above cataracts are caused by MIP gene mutations.
Porcine MIP gene information: encodes the major endogenous proteins of lens fiber cells; is located on chromosome 5; geneID is 100522373, sus scrofa.
The amino acid sequence coded by the swine MIP gene is shown as SEQ ID NO: shown in fig. 8.
The porcine MIP gene has the sequence shown in SEQ ID NO:9, or a fragment of DNA as set forth in seq id no.
Any of the above cataracts may be congenital cataracts.
Compared with the prior art, the invention has at least the following beneficial effects:
(1) The subject of the invention (pig) has better applicability than other animals (rat, primate).
Rodents such as rats and mice have great differences from humans in body types, organ sizes, physiology, pathology and the like, and cannot truly simulate normal physiological and pathological states of humans. Studies have shown that over 95% of drugs validated to be effective in large mice are not effective in human clinical trials. In large animals, primates are animals that have a close relationship with humans, but are small in size, late in sexual maturity (mating starts at age 6-7), and are single-birth animals, and the population propagation speed is extremely slow, and the raising cost is high. In addition, the cloning efficiency of the primate is low, the difficulty is high and the cost is high.
However, pigs are animals that have been closely related to humans except primates, and have body shapes, body weights, organ sizes, and the like similar to those of humans, and are very similar to those of humans in terms of anatomy, physiology, immunology, nutritional metabolism, disease pathogenesis, and the like. Meanwhile, the pigs have early sexual maturity (4-6 months), high reproductive capacity and multiple piglets, and can form a large group within 2-3 years. In addition, the cloning technology of the pig is very mature, and the cloning and breeding cost is much lower than that of the primate. Pigs are therefore very suitable animals as models for human disease.
(2) The vector constructed by the invention uses a strong promoter T7-lac which can express target protein with high efficiency to express the target protein, and uses a signal peptide of bacterial periplasmic protein alkaline phosphatase (phoA) to guide the secretion and expression of the target protein to a bacterial periplasm cavity, so that the target protein is separated from the bacterial intracellular protein and is expressed in a soluble way. Meanwhile, the thioredoxin TrxA and the Cas9 protein are fused and expressed, the TrxA can help the coexpressed target protein to form a disulfide bond, the stability and the folding correctness of the protein are improved, and the solubility and the activity of the target protein are increased. In order to facilitate the purification of the target protein, the His label is designed, and the target protein can be purified through one-step Ni column affinity chromatography, so that the purification process of the target protein is greatly simplified. Meanwhile, an enterokinase enzyme cutting site is designed behind the His tag, so that the fused TrxA-His polypeptide fragment can be conveniently cut off, and the Cas9 protein in a natural form can be obtained. After the fusion protein is digested by using the enterokinase with the His tag, the TrxA-His polypeptide fragment and the enterokinase with the His tag can be removed through one-time affinity chromatography to obtain the Cas9 protein in a natural form, so that the damage and loss of the target protein caused by multiple times of purification dialysis are avoided. Meanwhile, an NLS site is respectively designed at the N end and the C end of the Cas9, so that the Cas9 can more effectively enter a cell nucleus for gene editing. In addition, the E.coli BL21 (DE 3) strain is selected as a target protein expression strain, and the strain can efficiently express and clone the exogenous gene of an expression vector (such as pET-32 a) containing a bacteriophage T7 promoter. Meanwhile, as for the codon of the Cas9 protein, the codon optimization is carried out, so that the codon preference of the expression strain is completely adapted, and the expression level of the target protein is improved. In addition, after the bacteria grow to a certain amount, IPTG is used for inducing the expression of the target protein at low temperature, so that the influence of the premature expression of the target protein on the growth of host bacteria can be avoided, and the solubility of the expressed target protein is also obviously improved by inducing the expression at low temperature. Through the optimization design and experimental implementation of the above items, the activity of the obtained Cas9 protein is significantly improved compared with that of a commercial Cas9 protein.
(3) The gene editing is carried out by combining the Cas9 high-efficiency protein constructed and expressed with the gRNA transcribed in vitro, the optimal dosage ratio of the Cas9 and the gRNA is optimized, and the ratio of finally obtained gene editing single-cell clone is as high as 85.7 percent and is far higher than the conventional gene editing efficiency (10-30 percent).
(4) The invention adopts the combination of double gRNAs for mutation, and can effectively reduce the generation of non-frameshift mutation compared with the single gRNA. If a single gRNA is used to mutate a target gene, there is a 1/3 probability of generating a non-frameshift mutation of the base in random repair of non-homologous end joining (NHEJ) of the DNA, and the non-frameshift mutation is likely to fail to destroy the function of the target gene and fail to achieve the intended goal of inactivating the target gene. When the double gRNA is used for cutting and mutating the target gene, a fragment can be removed from the target gene, and the fragment deletion frame shift mutation of the target gene can be effectively generated by designing a base fragment with non-3 times removed. In addition, the double gRNA can cause theoretical fragment deletion, and the condition of respectively and independently cutting single gRNA also exists, so that the gene mutation efficiency is greatly increased.
(5) The cloned pig with the knocked-out target gene can be directly obtained by cloning somatic cell nuclear transfer animals by using the obtained single cell cloned strain with the knocked-out target gene, and the gene variation can be stably inherited.
The method for embryo transplantation after injecting gene editing materials into germ cells in micro-injection in mouse model production is not suitable for producing large animal (such as pig) models with longer gestation period because the probability of directly obtaining gene mutation offspring is lower and the offspring hybridization breeding is needed. Therefore, the method adopts the primary cell in-vitro editing with great technical difficulty and high challenge, the double gRNA cutting and the screening of the positive editing single cell clone, and the corresponding disease model pig is directly obtained through the somatic cell nuclear transfer animal cloning technology in the later stage, so that the model pig manufacturing period can be greatly shortened, and the manpower, material resources and financial resources are saved.
The invention adopts CRISPR/Cas9 technology combined with double gRNA editing to knock out MIP gene, simulates the genetic characteristics of natural onset of cataract, obtains single cell clone of MIP gene knock-out, and lays a foundation for cultivating cataract model pigs by somatic cell nuclear transfer animal cloning technology in the later period. The invention is helpful for researching and revealing the pathogenesis of cataract caused by MIP gene dysfunction, can also be used for researching drug screening, drug effect evaluation, gene therapy, cell therapy and the like, can provide effective experimental data for further clinical application, and further provides powerful experimental means for successfully treating human cataract. The invention has great application value for researching and developing cataract drugs and disclosing pathogenesis of the cataract.
Drawings
FIG. 1 is a schematic diagram of the structure of plasmid pET-32 a.
FIG. 2 is a schematic diagram of the structure of plasmid pKG-GE4.
FIG. 3 is an electrophoretogram of the optimized dosage ratio of gRNA and NCN protein in example 3.
Fig. 4 is an electrophoretogram comparing gene editing efficiency of NCN protein and a commercial Cas9 protein in example 3.
FIG. 5 is an electrophoretogram of PCR amplification using different primer pairs using ear tissue-extracted genomes of swine designated as 1 as templates in example 4.
FIG. 6 is an electrophoretogram of PCR amplification using primer pairs consisting of MIP-E3g-JDF33 and MIP-E3g-JDR528 in example 4 using genomic DNA of 18 pigs, respectively, as a template.
FIG. 7 is an electropherogram comparing the editing efficiency of different target combinations in example 4.
FIG. 8 is an alignment of reverse sequencing of single cell clone numbered 2 with the wild type sequence.
FIG. 9 is an alignment of reverse sequencing of single cell clone numbered 1 with the wild type sequence.
FIG. 10 is a forward and reverse sequencing of single cell clone numbered 3 aligned simultaneously with the wild type sequence.
FIG. 11 is an alignment of reverse sequencing of single cell clone number 5 with the wild type sequence.
Detailed Description
The present invention is described in further detail below with reference to specific embodiments, which are given for the purpose of illustration only and are not intended to limit the scope of the invention. The examples provided below serve as a guide for further modifications by a person skilled in the art and do not constitute a limitation of the invention in any way.
The experimental procedures in the following examples, unless otherwise indicated, are conventional and are carried out according to the techniques or conditions described in the literature in the field or according to the instructions of the products. Materials, reagents and the like used in the following examples are commercially available unless otherwise specified. The recombinant plasmids constructed in the examples were all sequence-verified. The commercial Cas9-a protein is a commercially available Cas9 protein with good effect. The commercial Cas9-B protein is a commercial Cas9 protein with good effect. Complete culture broth (% by volume): 15% fetal bovine serum (Gibco) +83% DMEM medium (Gibco) +1% Penicilin-Streptomyces (Gibco) +1% HEPES (Solarbio). Cell culture conditions: 37 ℃,5% of CO 2 、5％O 2 The constant temperature incubator.
The porcine primary fibroblasts used in the examples were all prepared from porcine ear tissue of Jiangxiang pigs, which was freshly harvested. The method for preparing the primary pig fibroblasts comprises the following steps: (1) taking 0.5g of pig ear tissue, removing hair and bone tissue, soaking in 75% alcohol for 30-40s, washing with PBS buffer containing 5% (volume ratio) Penicillin-Streptomycin (Gibco) for 5 times, and washing with PBS buffer for one time; (2) shearing the tissue with scissors, digesting with 5mL of 0.1% collagenase solution (Sigma) at 37 ℃ for 1h, centrifuging 500g for 5min, and removing the supernatant; (3) resuspending the precipitate with 1mL of complete culture solution, spreading into a 10cm diameter cell culture dish containing 10mL of complete culture solution and sealed with 0.2% gelatin (VWR), and culturing until the bottom of the dish is 60% full of cells; (4) after completion of step (3), the cells were digested with trypsin and collected, and then resuspended in complete medium. Used for carrying out subsequent electrotransfer experiments.
Example 1 construction of prokaryotic Cas9 high-efficiency expression vector
The structure of plasmid pET-32a is schematically shown in FIG. 1.
The plasmid pKG-GE4 is obtained by modifying plasmid pET-32a serving as a starting plasmid. Plasmid pET32a-T7lac-phoA SP-TrxA-His-EK-NLS-spCas9-NLS-T7ter (plasmid pKG-GE4 for short), as shown in SEQ ID NO:1, is a circular plasmid, and the structural schematic diagram is shown in figure 2.
SEQ ID NO:1, the 5121-5139 th nucleotide constitutes T7 promoter, the 5140-5164 th nucleotide encodes Lac operator (Lac operator), the 5178-5201 th nucleotide constitutes Ribosome Binding Site (RBS), the 5209-5271 th nucleotide encodes alkaline phosphatase signal peptide (phoA signal peptide), the 5272-5598 th nucleotide encodes TrxA protein, and the 5620-5637 th nucleotide encodes His-Tag (also called His-Tag) 6 Tag), 5638-5652 nucleotides encode enterokinase cleavage site (EK cleavage site), 5656-5670 nucleotides encode nuclear localization signal, 5701-9801 nucleotides encode spCas9 protein, 9802-9849 nucleotides encode nuclear localization signal, and 9902-9949 nucleotides constitute T7 terminator. The nucleotides encoding the spCas9 protein have been codon optimized for the e.coli BL21 (DE 3) strain.
The main modifications of plasmid pKG-GE4 are as follows: (1) the encoding region of the TrxA protein is reserved, and the TrxA protein can help the expressed target protein to form a disulfide bond and increase the solubility and the activity of the target protein; adding a coding sequence of an alkaline phosphatase signal peptide before a coding region of the TrxA protein, wherein the alkaline phosphatase signal peptide can guide the expressed target protein to be secreted into the periplasmic cavity of the bacteria and can be cut by prokaryotic periplasmic signal peptidase; (2) adding a coding sequence of His-Tag after the coding sequence of the TrxA protein, wherein the His-Tag can be used for enriching the expressed target protein; (3) adding the coding sequence of an enterokinase enzyme cutting site DDDDK (Asp-Asp-Asp-Asp-Lys) at the downstream of the coding sequence of the His-Tag, and removing the His-Tag and the upstream fused TrxA protein by the purified protein under the action of enterokinase; (4) the Cas9 gene which is suitable for being expressed by an escherichia coli BL21 (DE 3) strain after codon optimization is inserted, and meanwhile, the nuclear localization signal coding sequence is added at the upstream and the downstream of the gene, so that the nuclear localization capability of the Cas9 protein purified at the later stage is improved.
The fusion gene in the plasmid pKG-GE4 is shown as SEQ ID NO:1, nucleotides 5209 to 9852 of SEQ ID NO:2 (fusion protein TrxA-His-EK-NLS-spCas9-NLS, abbreviated as PRONCN protein). Due to the existence of the alkaline phosphatase signal peptide and the enterokinase enzyme cutting site, the fusion protein is cut by enterokinase enzyme to form SEQ ID NO:3, the protein shown in SEQ ID NO: the protein shown in 3 is named NCN protein.
Example 2 preparation and purification of NCN protein
1. Inducible expression
1. The plasmid pKG-GE4 was introduced into E.coli BL21 (DE 3) to obtain a recombinant strain.
2. The recombinant strain obtained in step 1 was inoculated into a liquid LB medium containing 100. Mu.g/ml ampicillin and cultured overnight at 37 ℃ with shaking at 200 rpm.
3. Inoculating the bacterial liquid obtained in the step 2 to a liquid LB culture medium, and carrying out shaking culture at 30 ℃ and 230rpm until the bacterial liquid is OD 600nm The value =1.0, isopropyl thiogalactoside (IPTG) was added to the system to give a concentration of 0.5mM, and the system was cultured at 25 ℃ for 12 hours with shaking at 230rpm, and then centrifuged at 4 ℃ for 15 minutes at 10000g, and the cells were collected.
4. The cells obtained in step 3 were washed with PBS buffer.
2. Purification of fusion protein TrxA-His-EK-NLS-spCas9-NLS
1. And (3) adding the crude extraction buffer solution into the thallus obtained in the step one, suspending the thallus, then crushing the thallus by using a homogenizer (1000 par circulation is carried out for three times), then centrifuging for 30min at 4 ℃ at 15000g, collecting supernatant, filtering the supernatant by using a filter membrane with the aperture of 0.22 mu m, and collecting filtrate. In this step, 10ml of crude extraction buffer solution is prepared for each g of wet-weight thallus.
Crude extraction buffer: containing 20mM Tris-HCl (pH 8.0), 0.5M NaCl, 5mM Imidazole, 1mM PMSF, and the balance ddH 2 O。
2. The fusion protein was purified by affinity chromatography.
Firstly, balancing a Ni-NTA agarose column by using a balance solution with 5 column volumes (the flow rate is 1 ml/min); then 50ml of the filtrate obtained in step 1 was loaded (flow rate 0.5-1 ml/min); the column was then washed with 5 column volumes of equilibration solution (flow rate 1 ml/min); the column was then washed with 5 column volumes of buffer (flow rate 1 ml/min) to remove contaminating proteins; then eluting with 10 column volumes of eluent at a flow rate of 0.5-1ml/min, and collecting the solution (90-100 ml) after passing through the column.
Ni-NTA agarose column: ausrey, L00250/L00250-C, 10ml of filler.
Balance liquid: containing 20mM Tris-HCl (pH 8.0), 0.5M NaCl, 5mM Imidazole, and the balance ddH 2 O。
Buffer solution: containing 20mM Tris-HCl (pH 8.0), 0.5M NaCl, 50mM Imidazole, and the balance ddH 2 O。
Eluent: containing 20mM Tris-HCl (pH 8.0), 0.5M NaCl, 500mM Imidazole, and the balance ddH 2 O。
3. Enzyme digestion of fusion protein TrxA-His-EK-NLS-spCas9-NLS and purification of NCN protein
1. 15ml of the post-column solution collected in step two was concentrated to 200. Mu.l using Amicon ultrafiltration tube (Sigma, UFC9100, 15ml capacity) and then diluted to 1ml with 25mM Tris-HCl (pH 8.0). 6 ultrafiltration tubes were used to give a total of 6ml.
2. Providing commercial source with His 6 Tagged recombinant bovine enterokinase (Bio, C620031, recombinant bovine enterokinase light chain with His) 6 The tag, recombinant Bovine Enterokinase Light Chain, his), was added to the solution (about 6 ml) obtained in step 1, and cleaved at 25 ℃ for 16 hours. 2 units of enterokinase are added in the amount of each 50 mug protein.
3. The solution (about 6 ml) that completed step 2 was taken and mixed with 480. Mu.l of Ni-NTA resin (Kinseri, L00250/L00250-C), mixed by rotation at room temperature for 15min, and then 7000g was centrifuged for 3min, and the supernatant (4-5.5 ml) was collected.
4. And (3) taking the supernatant obtained in the step (3), concentrating the supernatant to 200 mu l by using an Amicon ultrafiltration tube (Sigma, UFC9100, the volume of which is 15 ml), adding the concentrated solution into an enzyme stock solution, and adjusting the protein concentration to be 5mg/ml to obtain the NCN protein solution.
And (3) sequencing the protein in the NCN protein solution, wherein the 15N-terminal amino acid residues are shown as SEQ ID NO:3, positions 1 to 15, i.e., the NCN protein.
The NCN proteins used in the subsequent examples were all provided by NCN protein solutions.
Enzyme stock solution (ph 7.4): containing 10mM Tris,300mM NaCl,0.1mM EDTA,1mM DTT,50% (by volume) glycerol, and the balance ddH 2 O。
Example 3 Performance of NCN proteins
The 2 gRNA targets targeting the TTN gene were selected as follows:
TTN-gRNA1：AGAGCACAGTCAGCCTGGCG；
TTN-gRNA2：CTTCCAGAATTGGATCTCCG。
primers used to identify target fragments comprising grnas in the TTN gene were as follows:
TTN-F55：TACGGAATTGGGGAGCCAGCGGA；
TTN-R560：CAAAGTTAACTCTCTGTGTCT。
1. preparation of gRNA
1. Preparing TTN-T7-gRNA1 transcription template and TTN-T7-gRNA2 transcription template
The TTN-T7-gRNA1 transcription template is a double-stranded DNA molecule, and is shown as SEQ ID NO:4, respectively.
The TTN-T7-gRNA2 transcription template is a double-stranded DNA molecule, and is shown as SEQ ID NO:5, respectively.
2. In vitro transcription to obtain gRNA
Taking TTN-T7-gRNA1 Transcription template, adopting Transcript Aid T7 High Yield Transcription Kit (Fermentas, K0441) to carry out in vitro Transcription, and then using MEGA clear TM Transfer Clean-Up Kit (Thermo, AM 1908)Recovering and purifying to obtain TTN-gRNA1.TTN-gRNA1 is a single-stranded RNA, as shown in SEQ ID NO: and 6.
Taking TTN-T7-gRNA2 Transcription template, adopting a Transcription Aid T7 High Yield Transcription Kit (Fermentas, K0441) to carry out in vitro Transcription, and then using MEGA clear TM The Transcription Clean-Up Kit (Thermo, AM 1908) was recovered and purified to obtain TTN-gRNA2.TTN-gRNA2 is a single-stranded RNA, as shown in SEQ ID NO: shown at 7.
2. gRNA and NCN protein dosage proportion optimization
1. Co-transfected porcine primary fibroblasts
A first group: co-transfecting primary pig fibroblasts with TTN-gRNA1, TTN-gRNA2 and NCN protein. Proportioning: about 10 million porcine primary fibroblasts: 0.5 μ g TTN-gRNA1:0.5 μ g TTN-gRNA2: mu.g NCN protein.
Second group: co-transfecting the porcine primary fibroblasts with TTN-gRNA1, TTN-gRNA2 and NCN proteins. Proportioning: about 10 million porcine primary fibroblasts: 0.75 μ g TTN-gRNA1:0.75 μ g TTN-gRNA2: mu.g NCN protein.
Third group: co-transfecting primary pig fibroblasts with TTN-gRNA1, TTN-gRNA2 and NCN protein. Proportioning: about 10 million porcine primary fibroblasts: 1 μ g TTN-gRNA1:1 μ g TTN-gRNA2: mu.g NCN protein.
And a fourth group: co-transfecting the porcine primary fibroblasts with TTN-gRNA1, TTN-gRNA2 and NCN proteins. Proportioning: about 10 million porcine primary fibroblasts: 1.25 μ g TTN-gRNA1:1.25 μ g TTN-gRNA2: mu.g NCN protein.
And a fifth group: co-transfecting the porcine primary fibroblasts with TTN-gRNA1 and TTN-gRNA2. Proportioning: about 10 million porcine primary fibroblasts: 1 μ g TTN-gRNA1:1 μ g TTN-gRNA2.
Co-transfection was performed by electroporation using a mammalian nuclear transfection kit (Neon kit, thermofeisher) and a Neon TM transfection system electrotransfer instrument (parameters set at 1450V, 10ms, 3 pulses).
2. After step 1, the culture is carried out for 12 to 18 hours by using the complete culture solution, and then the culture is carried out by replacing the complete culture solution with a new one. The total time of incubation after electroporation was 48 hours.
3. After completion of step 2, cells were digested with trypsin and collected, genomic DNA was extracted, PCR amplified using a primer pair consisting of TTN-F55 and TTN-R560, and then subjected to 1% agarose gel electrophoresis.
The electrophoretogram is shown in FIG. 3. The 505bp band is a wild-type band (WT), and the about 254bp band (the wild-type band is 505bp theoretically deleted by 251 bp) is a deletion mutant band (MT).
Gene deletion mutation efficiency = (MT grayscale/MT band bp number)/(WT grayscale/WT band bp number + MT grayscale/MT band bp number) × 100%. The deletion mutation efficiency of the first group of genes is 19.9 percent, the deletion mutation efficiency of the second group of genes is 39.9 percent, the deletion mutation efficiency of the third group of genes is 79.9 percent, and the deletion mutation efficiency of the fourth group of genes is 44.3 percent. The fifth group was not mutated.
The result shows that when the mass ratio of the two gRNAs to the NCN protein is 1:1:4, the actual dosage is 1 mu g:1 μ g: the gene editing efficiency is highest at 4 mug. Thus, the optimal amount of two grnas and NCN proteins was determined to be 1 μ g:1 μ g:4 μ g.
3. Comparison of Gene editing efficiency of NCN protein with that of the commercial Cas9 protein
1. Co-transfected primary porcine fibroblasts
Cas9-a group: co-transfecting TTN-gRNA1, TTN-gRNA2 and a commercial Cas9-A protein to a porcine primary fibroblast. Proportioning: about 10 million porcine primary fibroblasts: 1 μ g TTN-gRNA1:1 μ g TTN-gRNA2:4 μ g Cas9-A protein.
pKG-GE4 group: co-transfecting the porcine primary fibroblasts with TTN-gRNA1, TTN-gRNA2 and NCN proteins. Proportioning: about 10 ten thousand porcine primary fibroblasts: 1 μ g TTN-gRNA1:1 μ g TTN-gRNA2: mu.g NCN protein.
Cas9-B group: co-transfecting the TTN-gRNA1, the TTN-gRNA2 and a commercial Cas9-B protein into a pig primary fibroblast. Proportioning: about 10 ten thousand porcine primary fibroblasts: 1 μ g TTN-gRNA1:1 μ g TTN-gRNA2:4 μ g Cas9-B protein.
Control group: co-transfecting the TTN-gRNA1 and the TTN-gRNA2 to the pig primary fibroblasts. Proportioning: about 10 ten thousand porcine primary fibroblasts: 1 μ g TTN-gRNA1:1 μ g TTN-gRNA2.
Co-transfection was performed by electroporation using a mammalian nuclear transfection kit (Neon kit, thermofeisher) and a Neon TM transfection system electrotransfer instrument (parameters set at 1450V, 10ms, 3 pulses).
2. After the completion of step 1, the culture is carried out for 12 to 18 hours by using the complete culture solution, and then the culture is carried out by replacing with a new complete culture solution. The total time of incubation after electroporation was 48 hours.
3. After completion of step 2, cells were digested and collected with trypsin, genomic DNA was extracted, PCR amplified using a primer pair consisting of TTN-F55 and TTN-R560, and then subjected to 1% agarose gel electrophoresis.
The electrophoretogram is shown in FIG. 4. The gene deletion mutation efficiency with the commercial Cas9-a protein was 28.5%, the gene deletion mutation efficiency with the NCN protein was 85.6%, and the gene deletion mutation efficiency with the commercial Cas9-B protein was 16.6%.
The result shows that compared with the Cas9 protein which adopts a commodity, the NCN protein prepared by the invention can obviously improve the gene editing efficiency.
Example 4 screening of MIP Gene efficient gRNA target combinations
Porcine MIP gene information: encodes a major endogenous protein of lens fiber cells; is located on chromosome 5; geneID is 100522373, sus scrofa. The amino acid sequence of the protein coded by the swine MIP gene is shown as SEQ ID NO: shown in fig. 8. In the pig genome DNA, the MIP gene has 7 exons, and partial sequences (containing the 3 rd exon and 400bp of each of the upstream and downstream thereof) are shown as SEQ ID NO: shown at 9.
Plasmid pKG-GE3, a circular plasmid, as described in patent application 202010084343.6, SEQ ID NO:2, respectively. SEQ ID NO:2, nucleotides 395 to 680 form a CMV enhancer, nucleotides 682 to 890 form an EF1a promoter, nucleotides 986 to 1006 encode a Nuclear Localization Signal (NLS), nucleotides 1016 to 1036 encode a Nuclear Localization Signal (NLS), nucleotides 1037 to 5161 encode a Cas9 protein, nucleotides 5162 to 5209 encode a Nuclear Localization Signal (NLS), nucleotides 5219 to 5266 encode a Nuclear Localization Signal (NLS), nucleotides 5276 to 5332 encode a self-cleaving polypeptide P2A (the amino acid sequence of the self-cleaving polypeptide P2A is "ATNFSLLKQACGDVEENPGP", the cleavage site occurring from the cleavage site is between the first and second amino acid residues C-terminal), nucleotides 5333 to 6046 encode an EGFP protein, nucleotides 6056 to 609 encode a self-cleaving polypeptide T2A (the amino acid sequence of the self-cleaving polypeptide T2A is "EGLTCGVEENP", the cleavage site occurring from the first and second amino acid residues 617647), nucleotides 677647 to 6747 encode a RGBW 10 protein), and nucleotides 677647 to 6747 encode a RGBW 10 protein (RGBW) for short. SEQ ID NO:2, the 911-6706 th nucleotides form fusion gene to express fusion protein. Due to the presence of the self-cleaving polypeptide P2A and the self-cleaving polypeptide T2A, the fusion protein spontaneously forms the following three proteins: proteins with Cas9 protein, proteins with EGFP protein and proteins with Puro protein.
The pKG-U6gRNA vector, plasmid pKG-U6gRNA, is a circular plasmid, as described in patent application 202010084343.6, SEQ ID NO:3, respectively. SEQ ID NO:3, the 2280 th to 2539 th nucleotides form the hU6 promoter, and the 2558 th to 2637 th nucleotides are used for transcription to form a gRNA framework. When the recombinant plasmid is used, a DNA molecule (a target sequence binding region for forming gRNA through transcription) of about 20bp is inserted into the plasmid pKG-U6gRNA to form a recombinant plasmid, and the recombinant plasmid is transcribed in a cell to obtain the gRNA.
1. Conservation analysis of MIP gene default deletion region and adjacent genome sequence
18 newborn Jiangxiang pigs, wherein 10 females (named 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10) and 8 males (named A, B, C, D, E, F, G and H respectively) are provided.
MIP-E3g-JDF33：AGGGCCATATTTGCTGAGTTCTT；
MIP-E3g-JDR466：CACACTCACATACAATATCCCAG；
MIP-E3g-JDF60：ACCCTCTTCTATGTCTTCTTTGG；
MIP-E3g-JDR528：CCAGGGCTCTATGACTTCTTTAC。
The porcine ear tissue designated 1 was used to extract the genome as a template, PCR amplified with different primer pairs, and then subjected to 1% agarose gel electrophoresis. The electrophoretogram is shown in FIG. 5. In fig. 5: group 1: a primer pair consisting of MIP-E3g-JDF33 and MIP-E3g-JDR466 is adopted; group 2: MIP-E3g-JDF33 and MIP-E3g-JDR528 adopt the formed primer pair; group 3: a primer pair consisting of MIP-E3g-JDF60 and MIP-E3g-JDR466 is adopted; group 4: a primer pair consisting of MIP-E3g-JDF60 and MIP-E3g-JDR528 is used. As a result, it is preferable to amplify the target fragment using a primer pair consisting of MIP-E3g-JDF33 and MIP-E3g-JDR 528.
The genomic DNA of 18 pigs was used as templates, and PCR amplification was performed using a primer pair consisting of MIP-E3g-JDF33 and MIP-E3g-JDR528, followed by 1% agarose gel electrophoresis. The electrophoretogram is shown in FIG. 6. And recovering PCR amplification products, sequencing, and comparing and analyzing the sequencing result with the MIP gene sequence in the public database. A common conserved region in 18 pigs is selected for designing a gRNA target.
2. Screening target spots
And primarily screening a plurality of targets by screening NGG (avoiding possible mutation sites), and further screening 6 targets from the NGG through a preliminary experiment.
The 6 targets were as follows:
MIP-E3-gRNA1：GGTAACACTGTACAGAACAG；
MIP-E3-gRNA2：GGAAGGCGAAAGTGACGGCG；
MIP-E3-gRNA3：GAGACATCTGGGAGCCCACG；
MIP-E3-gRNA4：CTGCCATGTAGCAGAAGGCA；
MIP-E3-gRNA5：AGTGACGGCGGGGTTGACAT；
MIP-E3-gRNA6：CATCTGGGAGCCCACGAGGA。
3. preparation of gRNA
The plasmid pKG-U6gRNA was digested with the restriction enzyme BbsI, and the vector backbone (approximately 3kb linear large fragment) was recovered.
MIP-E3-gRNA1-S and MIP-E3-gRNA1-A are respectively synthesized, and then are mixed and annealed to obtain double-stranded DNA molecules with sticky ends. Double-stranded DNA molecule having cohesive ends and vectorBackbone ligation to obtain plasmid pKG-U6gRNA (MIP-E3-gRNA 1). Plasmid pKG-U6gRNA (MIP-E3-gRNA 1) expresses the nucleic acid sequence of SEQ ID NO:10 sgRNA MIP-E3-gRNA1 。
sgRNA MIP-E3-gRNA1 (SEQ ID NO：10)：
GGUAACACUGUACAGAACAGguuuuagagcuagaaauagcaaguuaaaauaaggcuaguccguuaucaacuugaaaaaguggcaccgagucggugcuuuu
MIP-E3-gRNA2-S and MIP-E3-gRNA2-A are respectively synthesized, then mixed and annealed to obtain double-stranded DNA molecules with sticky ends. The double-stranded DNA molecule with cohesive ends was ligated to a vector backbone to obtain plasmid pKG-U6gRNA (MIP-E3-gRNA 2). Plasmid pKG-U6gRNA (MIP-E3-gRNA 2) expresses the nucleic acid sequence of SEQ ID NO: 11-sgRNA MIP-E3-gRNA2 。
sgRNA MIP-E3-gRNA2 (SEQ ID NO：11)：
GGAAGGCGAAAGUGACGGCGguuuuagagcuagaaauagcaaguuaaaauaaggcuaguccguuaucaacuugaaaaaguggcaccgagucggugcuuuu
MIP-E3-gRNA3-S and MIP-E3-gRNA3-A are respectively synthesized, and then are mixed and annealed to obtain double-stranded DNA molecules with sticky ends. The double-stranded DNA molecule with cohesive ends was ligated to a vector backbone to obtain plasmid pKG-U6gRNA (MIP-E3-gRNA 3). Plasmid pKG-U6gRNA (MIP-E3-gRNA 3) expresses the nucleic acid sequence of SEQ ID NO:12 sgRNA MIP-E3-gRNA3 。
sgRNA MIP-E3-gRNA3 (SEQ ID NO：12)：
GAGACAUCUGGGAGCCCACGguuuuagagcuagaaauagcaaguuaaaauaaggcuaguccguuaucaacuugaaaaaguggcaccgagucggugcuuuu
MIP-E3-gRNA4-S and MIP-E3-gRNA4-A are respectively synthesized, then mixed and annealed to obtain double-stranded DNA molecules with sticky ends. Double-stranded DNA molecules with cohesive ends are connected with a vector skeleton to obtain a plasmid pKG-U6gRNA (MIP-E3-gRNA 4). Plasmid pKG-U6gRNA (MIP-E3-gRNA 4) expresses the nucleic acid sequence of SEQ ID NO:13 sgRNA MIP-E3-gRNA4 。
sgRNA MIP-E3-gRNA4 (SEQ ID NO：13)：
CUGCCAUGUAGCAGAAGGCAguuuuagagcuagaaauagcaaguuaaaauaaggcuaguccguuaucaacuugaaaaaguggcaccgagucggugcuuuu
MIP-E3-gRNA5-S and MIP-E3-gRNA5-A are respectively synthesized, then mixed and annealed to obtain double-stranded DNA molecules with sticky ends. The double-stranded DNA molecule with cohesive ends was ligated to a vector backbone to obtain plasmid pKG-U6gRNA (MIP-E3-gRNA 5). Plasmid pKG-U6gRNA (MIP-E3-gRNA 5) expresses the nucleic acid sequence of SEQ ID NO:14 sgRNA MIP-E3-gRNA5 。
sgRNA MIP-E3-gRNA5 (SEQ ID NO：14)：
AGUGACGGCGGGGUUGACAUguuuuagagcuagaaauagcaaguuaaaauaaggcuaguccguuaucaacuugaaaaaguggcaccgagucggugcuuuu
MIP-E3-gRNA6-S and MIP-E3-gRNA6-A are respectively synthesized, then mixed and annealed to obtain double-stranded DNA molecules with sticky ends. The double-stranded DNA molecule with cohesive ends was ligated to a vector backbone to obtain plasmid pKG-U6gRNA (MIP-E3-gRNA 6). Plasmid pKG-U6gRNA (MIP-E3-gRNA 6) expresses the nucleic acid sequence of SEQ ID NO:15 sgRNA MIP-E3-gRNA6 。
sgRNA MIP-E3-gRNA6 (SEQ ID NO：15)：
CAUCUGGGAGCCCACGAGGAguuuuagagcuagaaauagcaaguuaaaauaaggcuaguccguuaucaacuugaaaaaguggcaccgagucggugcuuuu
MIP-E3-gRNA1-S：caccGGTAACACTGTACAGAACAG；
MIP-E3-gRNA1-A：aaacCTGTTCTGTACAGTGTTACC；
MIP-E3-gRNA2-S：caccGGAAGGCGAAAGTGACGGCG；
MIP-E3-gRNA2-A：aaacCGCCGTCACTTTCGCCTTCC；
MIP-E3-gRNA3-S：caccGAGACATCTGGGAGCCCACG；
MIP-E3-gRNA3-A：aaacCGTGGGCTCCCAGATGTCTC；
MIP-E3-gRNA4-S：caccgCTGCCATGTAGCAGAAGGCA；
MIP-E3-gRNA4-A：aaacTGCCTTCTGCTACATGGCAGc。
MIP-E3-gRNA5-S：caccgAGTGACGGCGGGGTTGACAT；
MIP-E3-gRNA5-A：aaacATGTCAACCCCGCCGTCACTc；
MIP-E3-gRNA6-S：caccgCATCTGGGAGCCCACGAGGA；
MIP-E3-gRNA6-A：aaacTCCTCGTGGGCTCCCAGATGc。
MIP-E3-gRNA1-S, MIP-E3-gRNA1-A, MIP-E3-gRNA2-S, MIP-E3-gRNA2-A, MIP-E3-gRNA3-S, MIP-E3-gRNA3-A, MIP-E3-gRNA4-S, MIP-E3-gRNA4-A, MIP-E3-gRNA5-S, MIP-E3-gRNA5-A, MIP-E3-gRNA6-S, MIP-E3-gRNA6-A are single-stranded DNA molecules.
4. Comparison of editing efficiency for different target combinations
1. Cotransfection
A first group: the plasmid pKG-U6gRNA (MIP-E3-gRNA 1) and the plasmid pKG-GE3 were co-transfected into porcine primary fibroblasts. Proportioning: about 20 million porcine primary fibroblasts: 0.92 μ g plasmid pKG-U6gRNA (MIP-E3-gRNA 1): 1.08. Mu.g of plasmid pKG-GE3.
Second group: the plasmid pKG-U6gRNA (MIP-E3-gRNA 2) and the plasmid pKG-GE3 were co-transfected into porcine primary fibroblasts. Proportioning: about 20 ten thousand porcine primary fibroblasts: 0.92 μ g plasmid pKG-U6gRNA (MIP-E3-gRNA 2): 1.08. Mu.g of plasmid pKG-GE3.
Third group: the plasmid pKG-U6gRNA (MIP-E3-gRNA 3) and the plasmid pKG-GE3 were co-transfected into porcine primary fibroblasts. Proportioning: about 20 million porcine primary fibroblasts: 0.92 μ g plasmid pKG-U6gRNA (MIP-E3-gRNA 3): 1.08. Mu.g of plasmid pKG-GE3.
And a fourth group: the plasmid pKG-U6gRNA (MIP-E3-gRNA 4) and the plasmid pKG-GE3 were co-transfected into porcine primary fibroblasts. Proportioning: about 20 million porcine primary fibroblasts: 0.92 μ g plasmid pKG-U6gRNA (MIP-E3-gRNA 4): 1.08. Mu.g of plasmid pKG-GE3.
A fifth group: the plasmid pKG-U6gRNA (MIP-E3-gRNA 5) and the plasmid pKG-GE3 were co-transfected into porcine primary fibroblasts. Proportioning: about 20 million porcine primary fibroblasts: 0.92 μ g plasmid pKG-U6gRNA (MIP-E3-gRNA 5): 1.08. Mu.g of plasmid pKG-GE3.
A sixth group: the plasmid pKG-U6gRNA (MIP-E3-gRNA 6) and the plasmid pKG-GE3 were co-transfected into porcine primary fibroblasts. Proportioning: about 20 ten thousand porcine primary fibroblasts: 0.92 μ g plasmid pKG-U6gRNA (MIP-E3-gRNA 6): 1.08. Mu.g of plasmid pKG-GE3.
A seventh group: the primary pig fibroblast is subjected to electrotransformation operation without adding plasmid under the same electrotransformation parameters.
Co-transfection was performed by electroporation using a mammalian nuclear transfection kit (Neon kit, thermofeisher) and a Neon TM transfection system electrotransfer instrument (parameters set at 1450V, 10ms, 3 pulses).
2. After the completion of step 1, the culture is carried out for 12 to 18 hours by using the complete culture solution, and then the culture is carried out by replacing with a new complete culture solution. The total time of incubation after electroporation was 48 hours.
3. After step 2 was completed, cells were digested and collected with trypsin, lysed, genomic DNA was extracted, PCR amplified using a primer pair consisting of MIP-E3g-JDF33 and MIP-E3g-JDR528, and then subjected to 1% agarose gel electrophoresis. And detecting the mutation of the target gene of the cell, and an electrophoresis chart is shown in figure 7.
And cutting and recovering the target product, sending the target product to a sequencing company for sequencing, and analyzing a sequencing peak map by using a webpage version Synthego ICE tool to obtain the gene editing efficiency of different targets. The gene editing efficiencies of the first group to the sixth group were 16%, 34%, 57%, 5%, 13%, and 20% in this order, and no gene editing occurred in the seventh group. The result shows that the editing efficiency of MIP-E3-gRNA2 and MIP-E3-gRNA3 is higher.
Example 5 preparation of MIP Gene knockout Single cell clone from Jiangxiang pig
Two high-efficiency gRNA targets (MIP-E3-gRNA 2 and MIP-E3-gRNA 3) screened in the example 4 are selected.
1. Preparation of gRNA
1. Preparing MIP-T7-gRNA3 transcription template and MIP-T7-gRNA6 transcription template
The MIP-T7-gRNA2 transcription template is a double-stranded DNA molecule, and is shown as SEQ ID NO: shown at 16.
The MIP-T7-gRNA3 transcription template is a double-stranded DNA molecule, and is shown as SEQ ID NO: shown at 17.
2. In vitro transcription to obtain gRNA
Taking MIP-T7-gRNA2 Transcription template, adopting a Transcription Aid T7 High Yield Transcription Kit (Fermentas, K0441) to carry out in vitro Transcription, and then using MEGA clear TM The MIP-gRNA2 was obtained by recovering and purifying the Transcription Clean-Up Kit (Thermo, AM 1908). MIP-gRNA2 is single-stranded RNA,as shown in SEQ ID NO:18, respectively.
MIP-gRNA2(SEQ ID NO：18)：
GGGGAAGGCGAAAGUGACGGCGGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUU
Taking MIP-T7-gRNA3 Transcription template, adopting Transcript Aid T7 High Yield Transcription Kit (Fermentas, K0441) to make in vitro Transcription, then using MEGA clear TM MIP-gRNA3 was obtained by recovering and purifying the Transcription Clean-Up Kit (Thermo, AM 1908). MIP-gRNA3 is single-stranded RNA, as shown in SEQ ID NO:19, respectively.
MIP-gRNA3(SEQ ID NO：19)：
GGGAGACAUCUGGGAGCCCACGGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUU
2. Transfection of porcine primary fibroblasts
1.MIP-gRNA2, MIP-gRNA3 and NCN protein are co-transfected into pig primary fibroblasts. Proportioning: about 10 ten thousand porcine primary fibroblasts: 1 μ g MIP-gRNA2:1 μ g MIP-gRNA3: mu.g NCN protein. Co-transfection was performed by electroporation using a mammalian nuclear transfection kit (Neon kit, thermofeisher) and a Neon TM transfection system electrotransfer instrument (parameters set at 1450V, 10ms, 3 pulses).
2. After step 1, the culture is carried out for 16 to 18 hours by using the complete culture solution, and then the culture is carried out by replacing the complete culture solution with a new one. The total time of incubation after electroporation was 48 hours.
3. After completion of step 2, cells were trypsinized and collected, then washed with complete medium, then resuspended with complete medium, and then each individual monoclonal was picked up and transferred to a 96-well plate (1 cell per well with 100. Mu.l of complete medium per well) for 2 weeks (replacement of new complete medium every 2-3 days).
4. After completion of step 3, cells were trypsinized and harvested (approximately 2/3 of the resulting cells per well were plated into 6-well plates containing complete medium, and the remaining 1/3 were harvested in 1.5mL centrifuge tubes).
5. The 6-well plate of step 4 was taken, cultured until the cells grew to 80% confluency, trypsinized and collected, and the cells were cryopreserved using cell cryopreserving (90% complete medium +10% dmso by volume).
6. And (4) taking the centrifuge tube in the step (4), taking cells, carrying out cell lysis and extracting genomic DNA, carrying out PCR amplification by adopting a primer pair consisting of MIP-E3g-JDF33 and MIP-E3g-JDR528, and then carrying out electrophoresis. Porcine primary fibroblasts were used as wild type controls (WT).
7. After completion of step 6, the PCR amplification product was recovered and sequenced.
Sequencing of porcine primary fibroblasts resulted in only one genotype, wild type (also called homozygous wild type). If the sequencing result of a single cell clone has two types, one type is consistent with the sequencing result of the pig primary fibroblast, and the other type has mutation (mutation comprises deletion, insertion or substitution of one or more nucleotides) compared with the sequencing result of the pig primary fibroblast, the genotype of the single cell clone is heterozygote; if the sequencing result of a single-cell clone is two, the single-cell clone is mutated (the mutation comprises deletion, insertion or substitution of one or more nucleotides) compared with the sequencing result of the pig primary fibroblast, and the genotype of the single-cell clone is a biallelic different mutant type; if the sequencing result of a single-cell clone is one and mutation (mutation comprises deletion, insertion or substitution of one or more nucleotides) is generated compared with the sequencing result of the pig primary fibroblast, the genotype of the single-cell clone is a biallelic identical mutant; if the sequencing result of a single cell clone is one and is consistent with the sequencing result of a pig primary fibroblast, the genotype of the single cell clone is a wild type (also called a homozygous wild type).
The results are shown in Table 1. The genotypes of the single cell clones numbered 2, 7, 20, 28, 32, 35 were wild-type. The genotypes of the single cell clones numbered 1, 4, 9, 13, 15, 18, 22, 23, 27, 30, 34, 37, 39 were heterozygous. The genotypes of the single cell clones numbered 3, 6, 11, 14, 16, 17, 19, 25, 29, 31, 33, 36, 38, 40, 41 are biallelically different mutants. The genotypes of the single cell clones numbered 5, 8, 10, 12, 21, 24, 26, 42 are biallelic identical mutants. The rate of single cell clones resulting in MIP gene editing was 85.7%.
Exemplary sequencing alignments are shown in figures 8 to 11. FIG. 8 shows the alignment of forward sequencing of single-cell clone No. 2 with the wild-type sequence, and the result was judged to be wild-type. FIG. 9 shows the alignment of forward sequencing of single-cell clone No. 1 with the wild-type sequence, and it was judged as heterozygous. FIG. 10 is a result of simultaneous alignment of forward and reverse sequencing of single cell clone numbered 3 with the wild type sequence, as biallelic different mutants. FIG. 11 is a result of alignment of forward sequencing of single cell clone numbered 5 with the wild type sequence, which is a biallelic identical mutant.
TABLE 1MIP Gene editing genotype determination results for single cell clones
Figure BDA0003208500000000151
Figure BDA0003208500000000161
Figure BDA0003208500000000171
The single cell clone of the heterozygote type, the different mutant types of the double alleles and the same mutant type of the double alleles can be used for subsequent clone pig production. The cells are used as nuclear transplantation donor cells to carry out somatic cell cloning, and cloned pigs, namely cataract model pigs, can be obtained.
The present invention has been described in detail above. It will be apparent to those skilled in the art that the invention can be practiced in a wide range of equivalent parameters, concentrations, and conditions without departing from the spirit and scope of the invention and without undue experimentation. While the invention has been described with reference to specific examples, it will be appreciated that the invention may be further modified. In general, this application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains. The use of some of the essential features is made possible within the scope of the claims attached below.
Sequence listing
<110> Nanjing King Gene engineering Co., ltd
<120> Gene editing System for constructing MIP Gene mutation model porcine Nuclear transplantation Donor cell and its application
<130> GNCYX212374
<160> 19
<170> SIPOSequenceListing 1.0
<210> 1
<211> 9974
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 1
tggcgaatgg gacgcgccct gtagcggcgc attaagcgcg gcgggtgtgg tggttacgcg 60
cagcgtgacc gctacacttg ccagcgccct agcgcccgct cctttcgctt tcttcccttc 120
ctttctcgcc acgttcgccg gctttccccg tcaagctcta aatcgggggc tccctttagg 180
gttccgattt agtgctttac ggcacctcga ccccaaaaaa cttgattagg gtgatggttc 240
acgtagtggg ccatcgccct gatagacggt ttttcgccct ttgacgttgg agtccacgtt 300
ctttaatagt ggactcttgt tccaaactgg aacaacactc aaccctatct cggtctattc 360
ttttgattta taagggattt tgccgatttc ggcctattgg ttaaaaaatg agctgattta 420
acaaaaattt aacgcgaatt ttaacaaaat attaacgttt acaatttcag gtggcacttt 480
tcggggaaat gtgcgcggaa cccctatttg tttatttttc taaatacatt caaatatgta 540
tccgctcatg agacaataac cctgataaat gcttcaataa tattgaaaaa ggaagagtat 600
gagtattcaa catttccgtg tcgcccttat tccctttttt gcggcatttt gccttcctgt 660
ttttgctcac ccagaaacgc tggtgaaagt aaaagatgct gaagatcagt tgggtgcacg 720
agtgggttac atcgaactgg atctcaacag cggtaagatc cttgagagtt ttcgccccga 780
agaacgtttt ccaatgatga gcacttttaa agttctgcta tgtggcgcgg tattatcccg 840
tattgacgcc gggcaagagc aactcggtcg ccgcatacac tattctcaga atgacttggt 900
tgagtactca ccagtcacag aaaagcatct tacggatggc atgacagtaa gagaattatg 960
cagtgctgcc ataaccatga gtgataacac tgcggccaac ttacttctga caacgatcgg 1020
aggaccgaag gagctaaccg cttttttgca caacatgggg gatcatgtaa ctcgccttga 1080
tcgttgggaa ccggagctga atgaagccat accaaacgac gagcgtgaca ccacgatgcc 1140
tgcagcaatg gcaacaacgt tgcgcaaact attaactggc gaactactta ctctagcttc 1200
ccggcaacaa ttaatagact ggatggaggc ggataaagtt gcaggaccac ttctgcgctc 1260
ggcccttccg gctggctggt ttattgctga taaatctgga gccggtgagc gtgggtctcg 1320
cggtatcatt gcagcactgg ggccagatgg taagccctcc cgtatcgtag ttatctacac 1380
gacggggagt caggcaacta tggatgaacg aaatagacag atcgctgaga taggtgcctc 1440
actgattaag cattggtaac tgtcagacca agtttactca tatatacttt agattgattt 1500
aaaacttcat ttttaattta aaaggatcta ggtgaagatc ctttttgata atctcatgac 1560
caaaatccct taacgtgagt tttcgttcca ctgagcgtca gaccccgtag aaaagatcaa 1620
aggatcttct tgagatcctt tttttctgcg cgtaatctgc tgcttgcaaa caaaaaaacc 1680
accgctacca gcggtggttt gtttgccgga tcaagagcta ccaactcttt ttccgaaggt 1740
aactggcttc agcagagcgc agataccaaa tactgtcctt ctagtgtagc cgtagttagg 1800
ccaccacttc aagaactctg tagcaccgcc tacatacctc gctctgctaa tcctgttacc 1860
agtggctgct gccagtggcg ataagtcgtg tcttaccggg ttggactcaa gacgatagtt 1920
accggataag gcgcagcggt cgggctgaac ggggggttcg tgcacacagc ccagcttgga 1980
gcgaacgacc tacaccgaac tgagatacct acagcgtgag ctatgagaaa gcgccacgct 2040
tcccgaaggg agaaaggcgg acaggtatcc ggtaagcggc agggtcggaa caggagagcg 2100
cacgagggag cttccagggg gaaacgcctg gtatctttat agtcctgtcg ggtttcgcca 2160
cctctgactt gagcgtcgat ttttgtgatg ctcgtcaggg gggcggagcc tatggaaaaa 2220
cgccagcaac gcggcctttt tacggttcct ggccttttgc tggccttttg ctcacatgtt 2280
ctttcctgcg ttatcccctg attctgtgga taaccgtatt accgcctttg agtgagctga 2340
taccgctcgc cgcagccgaa cgaccgagcg cagcgagtca gtgagcgagg aagcggaaga 2400
gcgcctgatg cggtattttc tccttacgca tctgtgcggt atttcacacc gcatatatgg 2460
tgcactctca gtacaatctg ctctgatgcc gcatagttaa gccagtatac actccgctat 2520
cgctacgtga ctgggtcatg gctgcgcccc gacacccgcc aacacccgct gacgcgccct 2580
gacgggcttg tctgctcccg gcatccgctt acagacaagc tgtgaccgtc tccgggagct 2640
gcatgtgtca gaggttttca ccgtcatcac cgaaacgcgc gaggcagctg cggtaaagct 2700
catcagcgtg gtcgtgaagc gattcacaga tgtctgcctg ttcatccgcg tccagctcgt 2760
tgagtttctc cagaagcgtt aatgtctggc ttctgataaa gcgggccatg ttaagggcgg 2820
ttttttcctg tttggtcact gatgcctccg tgtaaggggg atttctgttc atgggggtaa 2880
tgataccgat gaaacgagag aggatgctca cgatacgggt tactgatgat gaacatgccc 2940
ggttactgga acgttgtgag ggtaaacaac tggcggtatg gatgcggcgg gaccagagaa 3000
aaatcactca gggtcaatgc cagcgcttcg ttaatacaga tgtaggtgtt ccacagggta 3060
gccagcagca tcctgcgatg cagatccgga acataatggt gcagggcgct gacttccgcg 3120
tttccagact ttacgaaaca cggaaaccga agaccattca tgttgttgct caggtcgcag 3180
acgttttgca gcagcagtcg cttcacgttc gctcgcgtat cggtgattca ttctgctaac 3240
cagtaaggca accccgccag cctagccggg tcctcaacga caggagcacg atcatgcgca 3300
cccgtggggc cgccatgccg gcgataatgg cctgcttctc gccgaaacgt ttggtggcgg 3360
gaccagtgac gaaggcttga gcgagggcgt gcaagattcc gaataccgca agcgacaggc 3420
cgatcatcgt cgcgctccag cgaaagcggt cctcgccgaa aatgacccag agcgctgccg 3480
gcacctgtcc tacgagttgc atgataaaga agacagtcat aagtgcggcg acgatagtca 3540
tgccccgcgc ccaccggaag gagctgactg ggttgaaggc tctcaagggc atcggtcgag 3600
atcccggtgc ctaatgagtg agctaactta cattaattgc gttgcgctca ctgcccgctt 3660
tccagtcggg aaacctgtcg tgccagctgc attaatgaat cggccaacgc gcggggagag 3720
gcggtttgcg tattgggcgc cagggtggtt tttcttttca ccagtgagac gggcaacagc 3780
tgattgccct tcaccgcctg gccctgagag agttgcagca agcggtccac gctggtttgc 3840
cccagcaggc gaaaatcctg tttgatggtg gttaacggcg ggatataaca tgagctgtct 3900
tcggtatcgt cgtatcccac taccgagatg tccgcaccaa cgcgcagccc ggactcggta 3960
atggcgcgca ttgcgcccag cgccatctga tcgttggcaa ccagcatcgc agtgggaacg 4020
atgccctcat tcagcatttg catggtttgt tgaaaaccgg acatggcact ccagtcgcct 4080
tcccgttccg ctatcggctg aatttgattg cgagtgagat atttatgcca gccagccaga 4140
cgcagacgcg ccgagacaga acttaatggg cccgctaaca gcgcgatttg ctggtgaccc 4200
aatgcgacca gatgctccac gcccagtcgc gtaccgtctt catgggagaa aataatactg 4260
ttgatgggtg tctggtcaga gacatcaaga aataacgccg gaacattagt gcaggcagct 4320
tccacagcaa tggcatcctg gtcatccagc ggatagttaa tgatcagccc actgacgcgt 4380
tgcgcgagaa gattgtgcac cgccgcttta caggcttcga cgccgcttcg ttctaccatc 4440
gacaccacca cgctggcacc cagttgatcg gcgcgagatt taatcgccgc gacaatttgc 4500
gacggcgcgt gcagggccag actggaggtg gcaacgccaa tcagcaacga ctgtttgccc 4560
gccagttgtt gtgccacgcg gttgggaatg taattcagct ccgccatcgc cgcttccact 4620
ttttcccgcg ttttcgcaga aacgtggctg gcctggttca ccacgcggga aacggtctga 4680
taagagacac cggcatactc tgcgacatcg tataacgtta ctggtttcac attcaccacc 4740
ctgaattgac tctcttccgg gcgctatcat gccataccgc gaaaggtttt gcgccattcg 4800
atggtgtccg ggatctcgac gctctccctt atgcgactcc tgcattagga agcagcccag 4860
tagtaggttg aggccgttga gcaccgccgc cgcaaggaat ggtgcatgca aggagatggc 4920
gcccaacagt cccccggcca cggggcctgc caccataccc acgccgaaac aagcgctcat 4980
gagcccgaag tggcgagccc gatcttcccc atcggtgatg tcggcgatat aggcgccagc 5040
aaccgcacct gtggcgccgg tgatgccggc cacgatgcgt ccggcgtaga ggatcgagat 5100
cgatctcgat cccgcgaaat taatacgact cactataggg gaattgtgag cggataacaa 5160
ttcccctcta gaaataattt tgtttaactt taagaaggag atatacatat gaaacaaagc 5220
actattgcac tggcactctt accgttactg tttacccctg tgacaaaagc catgagcgat 5280
aaaattattc acctgactga cgacagtttt gacacggatg tactcaaagc ggacggggcg 5340
atcctcgtcg atttctgggc agagtggtgc ggtccgtgca aaatgatcgc cccgattctg 5400
gatgaaatcg ctgacgaata tcagggcaaa ctgaccgttg caaaactgaa catcgatcaa 5460
aaccctggca ctgcgccgaa atatggcatc cgtggtatcc cgactctgct gctgttcaaa 5520
aacggtgaag tggcggcaac caaagtgggt gcactgtcta aaggtcagtt gaaagagttc 5580
ctcgacgcta acctggccgg ttctggttct ggccatatgc accatcatca tcatcatgac 5640
gatgacgata agatgcccaa aaagaaacga aaggtgggta tccacggagt cccagcagcc 5700
gacaaaaaat atagcatcgg cctggacatc ggtaccaaca gcgttggctg ggcagtgatc 5760
actgatgaat acaaagttcc atccaaaaaa tttaaagtac tgggcaacac cgaccgtcac 5820
tctatcaaaa aaaacctgat tggtgctctg ctgtttgaca gcggcgaaac tgctgaggct 5880
acccgtctga aacgtacggc tcgccgtcgc tacactcgtc gtaaaaaccg catctgttat 5940
ctgcaggaaa ttttctctaa cgaaatggca aaagttgatg atagcttctt tcatcgtctg 6000
gaagagagct tcctggtgga agaagataaa aaacacgaac gtcacccgat tttcggtaac 6060
attgtggatg aggttgccta ccacgagaaa tatccgacca tctaccatct gcgtaaaaaa 6120
ctggttgata gcactgacaa agcggatctg cgtctgatct acctggctct ggcacacatg 6180
atcaaattcc gtggtcactt cctgatcgaa ggtgatctga accctgataa ctccgacgtg 6240
gacaaactgt tcattcagct ggttcagacc tataaccagc tgttcgaaga aaacccgatc 6300
aacgcgtccg gtgtagacgc taaggcaatt ctgtctgcgc gtctgtctaa gtctcgtcgt 6360
ctggaaaacc tgattgcgca actgccaggt gaaaagaaaa acggcctgtt cggcaatctg 6420
atcgccctgt ccctgggtct gactccgaac tttaaatcca actttgacct ggcggaagat 6480
gccaagctgc agctgagcaa agatacctat gacgatgacc tggataacct gctggcacag 6540
atcggtgatc agtatgccga tctgttcctg gccgcgaaaa acctgtctga tgcgattctg 6600
ctgtctgata tcctgcgcgt taacactgaa attactaaag cgccgctgag cgcatccatg 6660
attaaacgtt acgatgaaca ccaccaggat ctgaccctgc tgaaagcgct ggtgcgtcag 6720
cagctgccgg aaaaatacaa ggagatcttc ttcgaccaga gcaaaaacgg ttacgcgggc 6780
tacattgatg gtggtgcatc tcaggaggaa ttctacaaat tcattaaacc gatcctggaa 6840
aaaatggatg gtactgaaga gctgctggtt aaactgaatc gtgaagatct gctgcgcaaa 6900
cagcgtacct tcgataacgg ttccatcccg catcagattc atctgggcga actgcacgct 6960
atcctgcgcc gtcaggaaga cttttatccg ttcctgaaag acaaccgtga gaaaattgaa 7020
aaaatcctga ccttccgtat tccgtactat gtaggtccgc tggcgcgtgg taactcccgt 7080
ttcgcttgga tgacccgcaa aagcgaagaa accatcaccc cgtggaattt cgaagaagtc 7140
gttgacaaag gcgcgtccgc gcagtctttc atcgaacgca tgacgaactt cgacaaaaac 7200
ctgccgaacg agaaagtgct gccgaaacac tctctgctgt acgagtactt cactgtgtac 7260
aacgaactga ccaaagtgaa atacgtcacc gaaggtatgc gtaaaccggc attcctgtcc 7320
ggtgagcaaa aaaaagcaat cgtggatctg ctgttcaaaa ccaaccgtaa agtaaccgtg 7380
aaacagctga aggaagacta tttcaagaaa atcgaatgtt ttgattctgt tgaaatctcc 7440
ggcgtggaag atcgcttcaa tgcgtccctg ggtacgtatc acgacctgct gaaaattatc 7500
aaagacaaag attttctgga caacgaggaa aacgaagaca tcctggagga tattgtactg 7560
accctgaccc tgttcgaaga ccgtgagatg atcgaagaac gcctgaaaac ctacgcccac 7620
ctgttcgatg acaaggtaat gaagcagctg aaacgtcgtc gttataccgg ctggggtcgt 7680
ctgtcccgta aactgatcaa tggcatccgt gataaacagt ctggcaaaac catcctggac 7740
ttcctgaaat ccgacggttt cgcgaatcgt aacttcatgc aactgattca tgacgattct 7800
ctgactttca aagaagacat ccagaaagca caggtttccg gccagggtga ctctctgcac 7860
gagcacattg ccaatctggc tggttctccg gctattaaaa agggtattct gcagactgtg 7920
aaagtagttg atgagctggt caaagtaatg ggccgtcaca agccggaaaa cattgtgatc 7980
gaaatggcac gtgaaaacca gacgacccag aaaggtcaga aaaactctcg tgaacgcatg 8040
aaacgtatcg aagaaggcat caaagaactg ggctctcaga tcctgaagga acaccctgta 8100
gaaaataccc agctgcagaa cgaaaagctg tatctgtatt acctgcagaa cggccgcgat 8160
atgtatgtgg accaggaact ggatatcaac cgcctgtccg attacgatgt agatcacatc 8220
gtgccgcaaa gcttcctgaa agacgacagc attgacaaca aagtactgac ccgttctgat 8280
aagaaccgtg gcaaatccga taacgtcccg tctgaagaag ttgttaaaaa aatgaaaaac 8340
tattggcgtc agctgctgaa cgcgaaactg atcacccagc gtaagttcga caatctgact 8400
aaagctgagc gcggtggtct gtccgaactg gataaagcgg gttttatcaa acgccagctg 8460
gttgaaaccc gtcagatcac gaagcacgtt gcgcagattc tggactctcg tatgaacacc 8520
aaatacgacg aaaacgacaa actgatccgc gaggttaagg ttatcaccct gaaaagcaaa 8580
ctggtatccg attttcgtaa agactttcag ttctacaaag tgcgcgaaat taacaactat 8640
caccacgctc acgatgcata tctgaatgca gttgttggca cggcgctgat caaaaagtat 8700
ccgaaactgg aatctgaatt cgtatacggc gattacaaag tgtatgacgt tcgtaagatg 8760
atcgcaaaat ccgagcagga aattggtaag gcgacggcga aatacttctt ttattccaat 8820
attatgaact ttttcaaaac cgaaatcacc ctggcgaatg gtgaaattcg taaacgcccg 8880
ctgatcgaaa ccaacggtga aactggtgaa atcgtttggg acaaaggccg cgacttcgcg 8940
accgtgcgta aagttctgtc tatgccgcaa gtgaacatcg tcaagaagac cgaagtacaa 9000
accggcggtt ttagcaaaga gagcattctg ccaaaacgta actccgacaa actgatcgcg 9060
cgcaagaaag actgggatcc gaaaaaatac ggtggtttcg attctccaac cgttgcttat 9120
tccgttctgg tggtagccaa agttgagaaa ggtaaaagca aaaaactgaa atccgtaaag 9180
gaactgctgg gtattactat catggagcgt agctccttcg aaaaaaaccc gatcgatttt 9240
ctggaagcga aaggctataa agaagtcaaa aaggacctga tcatcaaact gccaaaatac 9300
agcctgttcg agctggaaaa cggccgtaaa cgtatgctgg catctgcggg cgaactgcag 9360
aaaggcaacg agctggctct gccgtccaaa tacgtgaact ttctgtacct ggcctctcac 9420
tacgaaaaac tgaaaggttc cccggaagac aacgaacaga aacagctgtt cgtagagcag 9480
cacaaacact acctggacga gatcatcgaa cagatttctg aattttctaa acgtgtgatt 9540
ctggctgatg cgaatctgga taaagttctg tctgcctata acaagcatcg tgacaaaccg 9600
atccgcgaac aggctgagaa catcatccac ctgttcactc tgactaacct gggcgcgcca 9660
gcggctttca agtactttga taccaccatt gaccgcaagc gttacacctc cactaaagaa 9720
gtgctggacg cgactctgat ccaccagtcc atcaccggtc tgtacgagac ccgtatcgat 9780
ctgagccagc tgggcggtga caaaaggccg gcggccacga aaaaggccgg ccaggcaaaa 9840
aagaaaaagt gacaaagccc gaaaggaagc tgagttggct gctgccaccg ctgagcaata 9900
actagcataa ccccttgggg cctctaaacg ggtcttgagg ggttttttgc tgaaaggagg 9960
aactatatcc ggat 9974
<210> 2
<211> 1547
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 2
Met Lys Gln Ser Thr Ile Ala Leu Ala Leu Leu Pro Leu Leu Phe Thr
1 5 10 15
Pro Val Thr Lys Ala Met Ser Asp Lys Ile Ile His Leu Thr Asp Asp
20 25 30
Ser Phe Asp Thr Asp Val Leu Lys Ala Asp Gly Ala Ile Leu Val Asp
35 40 45
Phe Trp Ala Glu Trp Cys Gly Pro Cys Lys Met Ile Ala Pro Ile Leu
50 55 60
Asp Glu Ile Ala Asp Glu Tyr Gln Gly Lys Leu Thr Val Ala Lys Leu
65 70 75 80
Asn Ile Asp Gln Asn Pro Gly Thr Ala Pro Lys Tyr Gly Ile Arg Gly
85 90 95
Ile Pro Thr Leu Leu Leu Phe Lys Asn Gly Glu Val Ala Ala Thr Lys
100 105 110
Val Gly Ala Leu Ser Lys Gly Gln Leu Lys Glu Phe Leu Asp Ala Asn
115 120 125
Leu Ala Gly Ser Gly Ser Gly His Met His His His His His His Asp
130 135 140
Asp Asp Asp Lys Met Pro Lys Lys Lys Arg Lys Val Gly Ile His Gly
145 150 155 160
Val Pro Ala Ala Asp Lys Lys Tyr Ser Ile Gly Leu Asp Ile Gly Thr
165 170 175
Asn Ser Val Gly Trp Ala Val Ile Thr Asp Glu Tyr Lys Val Pro Ser
180 185 190
Lys Lys Phe Lys Val Leu Gly Asn Thr Asp Arg His Ser Ile Lys Lys
195 200 205
Asn Leu Ile Gly Ala Leu Leu Phe Asp Ser Gly Glu Thr Ala Glu Ala
210 215 220
Thr Arg Leu Lys Arg Thr Ala Arg Arg Arg Tyr Thr Arg Arg Lys Asn
225 230 235 240
Arg Ile Cys Tyr Leu Gln Glu Ile Phe Ser Asn Glu Met Ala Lys Val
245 250 255
Asp Asp Ser Phe Phe His Arg Leu Glu Glu Ser Phe Leu Val Glu Glu
260 265 270
Asp Lys Lys His Glu Arg His Pro Ile Phe Gly Asn Ile Val Asp Glu
275 280 285
Val Ala Tyr His Glu Lys Tyr Pro Thr Ile Tyr His Leu Arg Lys Lys
290 295 300
Leu Val Asp Ser Thr Asp Lys Ala Asp Leu Arg Leu Ile Tyr Leu Ala
305 310 315 320
Leu Ala His Met Ile Lys Phe Arg Gly His Phe Leu Ile Glu Gly Asp
325 330 335
Leu Asn Pro Asp Asn Ser Asp Val Asp Lys Leu Phe Ile Gln Leu Val
340 345 350
Gln Thr Tyr Asn Gln Leu Phe Glu Glu Asn Pro Ile Asn Ala Ser Gly
355 360 365
Val Asp Ala Lys Ala Ile Leu Ser Ala Arg Leu Ser Lys Ser Arg Arg
370 375 380
Leu Glu Asn Leu Ile Ala Gln Leu Pro Gly Glu Lys Lys Asn Gly Leu
385 390 395 400
Phe Gly Asn Leu Ile Ala Leu Ser Leu Gly Leu Thr Pro Asn Phe Lys
405 410 415
Ser Asn Phe Asp Leu Ala Glu Asp Ala Lys Leu Gln Leu Ser Lys Asp
420 425 430
Thr Tyr Asp Asp Asp Leu Asp Asn Leu Leu Ala Gln Ile Gly Asp Gln
435 440 445
Tyr Ala Asp Leu Phe Leu Ala Ala Lys Asn Leu Ser Asp Ala Ile Leu
450 455 460
Leu Ser Asp Ile Leu Arg Val Asn Thr Glu Ile Thr Lys Ala Pro Leu
465 470 475 480
Ser Ala Ser Met Ile Lys Arg Tyr Asp Glu His His Gln Asp Leu Thr
485 490 495
Leu Leu Lys Ala Leu Val Arg Gln Gln Leu Pro Glu Lys Tyr Lys Glu
500 505 510
Ile Phe Phe Asp Gln Ser Lys Asn Gly Tyr Ala Gly Tyr Ile Asp Gly
515 520 525
Gly Ala Ser Gln Glu Glu Phe Tyr Lys Phe Ile Lys Pro Ile Leu Glu
530 535 540
Lys Met Asp Gly Thr Glu Glu Leu Leu Val Lys Leu Asn Arg Glu Asp
545 550 555 560
Leu Leu Arg Lys Gln Arg Thr Phe Asp Asn Gly Ser Ile Pro His Gln
565 570 575
Ile His Leu Gly Glu Leu His Ala Ile Leu Arg Arg Gln Glu Asp Phe
580 585 590
Tyr Pro Phe Leu Lys Asp Asn Arg Glu Lys Ile Glu Lys Ile Leu Thr
595 600 605
Phe Arg Ile Pro Tyr Tyr Val Gly Pro Leu Ala Arg Gly Asn Ser Arg
610 615 620
Phe Ala Trp Met Thr Arg Lys Ser Glu Glu Thr Ile Thr Pro Trp Asn
625 630 635 640
Phe Glu Glu Val Val Asp Lys Gly Ala Ser Ala Gln Ser Phe Ile Glu
645 650 655
Arg Met Thr Asn Phe Asp Lys Asn Leu Pro Asn Glu Lys Val Leu Pro
660 665 670
Lys His Ser Leu Leu Tyr Glu Tyr Phe Thr Val Tyr Asn Glu Leu Thr
675 680 685
Lys Val Lys Tyr Val Thr Glu Gly Met Arg Lys Pro Ala Phe Leu Ser
690 695 700
Gly Glu Gln Lys Lys Ala Ile Val Asp Leu Leu Phe Lys Thr Asn Arg
705 710 715 720
Lys Val Thr Val Lys Gln Leu Lys Glu Asp Tyr Phe Lys Lys Ile Glu
725 730 735
Cys Phe Asp Ser Val Glu Ile Ser Gly Val Glu Asp Arg Phe Asn Ala
740 745 750
Ser Leu Gly Thr Tyr His Asp Leu Leu Lys Ile Ile Lys Asp Lys Asp
755 760 765
Phe Leu Asp Asn Glu Glu Asn Glu Asp Ile Leu Glu Asp Ile Val Leu
770 775 780
Thr Leu Thr Leu Phe Glu Asp Arg Glu Met Ile Glu Glu Arg Leu Lys
785 790 795 800
Thr Tyr Ala His Leu Phe Asp Asp Lys Val Met Lys Gln Leu Lys Arg
805 810 815
Arg Arg Tyr Thr Gly Trp Gly Arg Leu Ser Arg Lys Leu Ile Asn Gly
820 825 830
Ile Arg Asp Lys Gln Ser Gly Lys Thr Ile Leu Asp Phe Leu Lys Ser
835 840 845
Asp Gly Phe Ala Asn Arg Asn Phe Met Gln Leu Ile His Asp Asp Ser
850 855 860
Leu Thr Phe Lys Glu Asp Ile Gln Lys Ala Gln Val Ser Gly Gln Gly
865 870 875 880
Asp Ser Leu His Glu His Ile Ala Asn Leu Ala Gly Ser Pro Ala Ile
885 890 895
Lys Lys Gly Ile Leu Gln Thr Val Lys Val Val Asp Glu Leu Val Lys
900 905 910
Val Met Gly Arg His Lys Pro Glu Asn Ile Val Ile Glu Met Ala Arg
915 920 925
Glu Asn Gln Thr Thr Gln Lys Gly Gln Lys Asn Ser Arg Glu Arg Met
930 935 940
Lys Arg Ile Glu Glu Gly Ile Lys Glu Leu Gly Ser Gln Ile Leu Lys
945 950 955 960
Glu His Pro Val Glu Asn Thr Gln Leu Gln Asn Glu Lys Leu Tyr Leu
965 970 975
Tyr Tyr Leu Gln Asn Gly Arg Asp Met Tyr Val Asp Gln Glu Leu Asp
980 985 990
Ile Asn Arg Leu Ser Asp Tyr Asp Val Asp His Ile Val Pro Gln Ser
995 1000 1005
Phe Leu Lys Asp Asp Ser Ile Asp Asn Lys Val Leu Thr Arg Ser Asp
1010 1015 1020
Lys Asn Arg Gly Lys Ser Asp Asn Val Pro Ser Glu Glu Val Val Lys
1025 1030 1035 1040
Lys Met Lys Asn Tyr Trp Arg Gln Leu Leu Asn Ala Lys Leu Ile Thr
1045 1050 1055
Gln Arg Lys Phe Asp Asn Leu Thr Lys Ala Glu Arg Gly Gly Leu Ser
1060 1065 1070
Glu Leu Asp Lys Ala Gly Phe Ile Lys Arg Gln Leu Val Glu Thr Arg
1075 1080 1085
Gln Ile Thr Lys His Val Ala Gln Ile Leu Asp Ser Arg Met Asn Thr
1090 1095 1100
Lys Tyr Asp Glu Asn Asp Lys Leu Ile Arg Glu Val Lys Val Ile Thr
1105 1110 1115 1120
Leu Lys Ser Lys Leu Val Ser Asp Phe Arg Lys Asp Phe Gln Phe Tyr
1125 1130 1135
Lys Val Arg Glu Ile Asn Asn Tyr His His Ala His Asp Ala Tyr Leu
1140 1145 1150
Asn Ala Val Val Gly Thr Ala Leu Ile Lys Lys Tyr Pro Lys Leu Glu
1155 1160 1165
Ser Glu Phe Val Tyr Gly Asp Tyr Lys Val Tyr Asp Val Arg Lys Met
1170 1175 1180
Ile Ala Lys Ser Glu Gln Glu Ile Gly Lys Ala Thr Ala Lys Tyr Phe
1185 1190 1195 1200
Phe Tyr Ser Asn Ile Met Asn Phe Phe Lys Thr Glu Ile Thr Leu Ala
1205 1210 1215
Asn Gly Glu Ile Arg Lys Arg Pro Leu Ile Glu Thr Asn Gly Glu Thr
1220 1225 1230
Gly Glu Ile Val Trp Asp Lys Gly Arg Asp Phe Ala Thr Val Arg Lys
1235 1240 1245
Val Leu Ser Met Pro Gln Val Asn Ile Val Lys Lys Thr Glu Val Gln
1250 1255 1260
Thr Gly Gly Phe Ser Lys Glu Ser Ile Leu Pro Lys Arg Asn Ser Asp
1265 1270 1275 1280
Lys Leu Ile Ala Arg Lys Lys Asp Trp Asp Pro Lys Lys Tyr Gly Gly
1285 1290 1295
Phe Asp Ser Pro Thr Val Ala Tyr Ser Val Leu Val Val Ala Lys Val
1300 1305 1310
Glu Lys Gly Lys Ser Lys Lys Leu Lys Ser Val Lys Glu Leu Leu Gly
1315 1320 1325
Ile Thr Ile Met Glu Arg Ser Ser Phe Glu Lys Asn Pro Ile Asp Phe
1330 1335 1340
Leu Glu Ala Lys Gly Tyr Lys Glu Val Lys Lys Asp Leu Ile Ile Lys
1345 1350 1355 1360
Leu Pro Lys Tyr Ser Leu Phe Glu Leu Glu Asn Gly Arg Lys Arg Met
1365 1370 1375
Leu Ala Ser Ala Gly Glu Leu Gln Lys Gly Asn Glu Leu Ala Leu Pro
1380 1385 1390
Ser Lys Tyr Val Asn Phe Leu Tyr Leu Ala Ser His Tyr Glu Lys Leu
1395 1400 1405
Lys Gly Ser Pro Glu Asp Asn Glu Gln Lys Gln Leu Phe Val Glu Gln
1410 1415 1420
His Lys His Tyr Leu Asp Glu Ile Ile Glu Gln Ile Ser Glu Phe Ser
1425 1430 1435 1440
Lys Arg Val Ile Leu Ala Asp Ala Asn Leu Asp Lys Val Leu Ser Ala
1445 1450 1455
Tyr Asn Lys His Arg Asp Lys Pro Ile Arg Glu Gln Ala Glu Asn Ile
1460 1465 1470
Ile His Leu Phe Thr Leu Thr Asn Leu Gly Ala Pro Ala Ala Phe Lys
1475 1480 1485
Tyr Phe Asp Thr Thr Ile Asp Arg Lys Arg Tyr Thr Ser Thr Lys Glu
1490 1495 1500
Val Leu Asp Ala Thr Leu Ile His Gln Ser Ile Thr Gly Leu Tyr Glu
1505 1510 1515 1520
Thr Arg Ile Asp Leu Ser Gln Leu Gly Gly Asp Lys Arg Pro Ala Ala
1525 1530 1535
Thr Lys Lys Ala Gly Gln Ala Lys Lys Lys Lys
1540 1545
<210> 3
<211> 1399
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 3
Met Pro Lys Lys Lys Arg Lys Val Gly Ile His Gly Val Pro Ala Ala
1 5 10 15
Asp Lys Lys Tyr Ser Ile Gly Leu Asp Ile Gly Thr Asn Ser Val Gly
20 25 30
Trp Ala Val Ile Thr Asp Glu Tyr Lys Val Pro Ser Lys Lys Phe Lys
35 40 45
Val Leu Gly Asn Thr Asp Arg His Ser Ile Lys Lys Asn Leu Ile Gly
50 55 60
Ala Leu Leu Phe Asp Ser Gly Glu Thr Ala Glu Ala Thr Arg Leu Lys
65 70 75 80
Arg Thr Ala Arg Arg Arg Tyr Thr Arg Arg Lys Asn Arg Ile Cys Tyr
85 90 95
Leu Gln Glu Ile Phe Ser Asn Glu Met Ala Lys Val Asp Asp Ser Phe
100 105 110
Phe His Arg Leu Glu Glu Ser Phe Leu Val Glu Glu Asp Lys Lys His
115 120 125
Glu Arg His Pro Ile Phe Gly Asn Ile Val Asp Glu Val Ala Tyr His
130 135 140
Glu Lys Tyr Pro Thr Ile Tyr His Leu Arg Lys Lys Leu Val Asp Ser
145 150 155 160
Thr Asp Lys Ala Asp Leu Arg Leu Ile Tyr Leu Ala Leu Ala His Met
165 170 175
Ile Lys Phe Arg Gly His Phe Leu Ile Glu Gly Asp Leu Asn Pro Asp
180 185 190
Asn Ser Asp Val Asp Lys Leu Phe Ile Gln Leu Val Gln Thr Tyr Asn
195 200 205
Gln Leu Phe Glu Glu Asn Pro Ile Asn Ala Ser Gly Val Asp Ala Lys
210 215 220
Ala Ile Leu Ser Ala Arg Leu Ser Lys Ser Arg Arg Leu Glu Asn Leu
225 230 235 240
Ile Ala Gln Leu Pro Gly Glu Lys Lys Asn Gly Leu Phe Gly Asn Leu
245 250 255
Ile Ala Leu Ser Leu Gly Leu Thr Pro Asn Phe Lys Ser Asn Phe Asp
260 265 270
Leu Ala Glu Asp Ala Lys Leu Gln Leu Ser Lys Asp Thr Tyr Asp Asp
275 280 285
Asp Leu Asp Asn Leu Leu Ala Gln Ile Gly Asp Gln Tyr Ala Asp Leu
290 295 300
Phe Leu Ala Ala Lys Asn Leu Ser Asp Ala Ile Leu Leu Ser Asp Ile
305 310 315 320
Leu Arg Val Asn Thr Glu Ile Thr Lys Ala Pro Leu Ser Ala Ser Met
325 330 335
Ile Lys Arg Tyr Asp Glu His His Gln Asp Leu Thr Leu Leu Lys Ala
340 345 350
Leu Val Arg Gln Gln Leu Pro Glu Lys Tyr Lys Glu Ile Phe Phe Asp
355 360 365
Gln Ser Lys Asn Gly Tyr Ala Gly Tyr Ile Asp Gly Gly Ala Ser Gln
370 375 380
Glu Glu Phe Tyr Lys Phe Ile Lys Pro Ile Leu Glu Lys Met Asp Gly
385 390 395 400
Thr Glu Glu Leu Leu Val Lys Leu Asn Arg Glu Asp Leu Leu Arg Lys
405 410 415
Gln Arg Thr Phe Asp Asn Gly Ser Ile Pro His Gln Ile His Leu Gly
420 425 430
Glu Leu His Ala Ile Leu Arg Arg Gln Glu Asp Phe Tyr Pro Phe Leu
435 440 445
Lys Asp Asn Arg Glu Lys Ile Glu Lys Ile Leu Thr Phe Arg Ile Pro
450 455 460
Tyr Tyr Val Gly Pro Leu Ala Arg Gly Asn Ser Arg Phe Ala Trp Met
465 470 475 480
Thr Arg Lys Ser Glu Glu Thr Ile Thr Pro Trp Asn Phe Glu Glu Val
485 490 495
Val Asp Lys Gly Ala Ser Ala Gln Ser Phe Ile Glu Arg Met Thr Asn
500 505 510
Phe Asp Lys Asn Leu Pro Asn Glu Lys Val Leu Pro Lys His Ser Leu
515 520 525
Leu Tyr Glu Tyr Phe Thr Val Tyr Asn Glu Leu Thr Lys Val Lys Tyr
530 535 540
Val Thr Glu Gly Met Arg Lys Pro Ala Phe Leu Ser Gly Glu Gln Lys
545 550 555 560
Lys Ala Ile Val Asp Leu Leu Phe Lys Thr Asn Arg Lys Val Thr Val
565 570 575
Lys Gln Leu Lys Glu Asp Tyr Phe Lys Lys Ile Glu Cys Phe Asp Ser
580 585 590
Val Glu Ile Ser Gly Val Glu Asp Arg Phe Asn Ala Ser Leu Gly Thr
595 600 605
Tyr His Asp Leu Leu Lys Ile Ile Lys Asp Lys Asp Phe Leu Asp Asn
610 615 620
Glu Glu Asn Glu Asp Ile Leu Glu Asp Ile Val Leu Thr Leu Thr Leu
625 630 635 640
Phe Glu Asp Arg Glu Met Ile Glu Glu Arg Leu Lys Thr Tyr Ala His
645 650 655
Leu Phe Asp Asp Lys Val Met Lys Gln Leu Lys Arg Arg Arg Tyr Thr
660 665 670
Gly Trp Gly Arg Leu Ser Arg Lys Leu Ile Asn Gly Ile Arg Asp Lys
675 680 685
Gln Ser Gly Lys Thr Ile Leu Asp Phe Leu Lys Ser Asp Gly Phe Ala
690 695 700
Asn Arg Asn Phe Met Gln Leu Ile His Asp Asp Ser Leu Thr Phe Lys
705 710 715 720
Glu Asp Ile Gln Lys Ala Gln Val Ser Gly Gln Gly Asp Ser Leu His
725 730 735
Glu His Ile Ala Asn Leu Ala Gly Ser Pro Ala Ile Lys Lys Gly Ile
740 745 750
Leu Gln Thr Val Lys Val Val Asp Glu Leu Val Lys Val Met Gly Arg
755 760 765
His Lys Pro Glu Asn Ile Val Ile Glu Met Ala Arg Glu Asn Gln Thr
770 775 780
Thr Gln Lys Gly Gln Lys Asn Ser Arg Glu Arg Met Lys Arg Ile Glu
785 790 795 800
Glu Gly Ile Lys Glu Leu Gly Ser Gln Ile Leu Lys Glu His Pro Val
805 810 815
Glu Asn Thr Gln Leu Gln Asn Glu Lys Leu Tyr Leu Tyr Tyr Leu Gln
820 825 830
Asn Gly Arg Asp Met Tyr Val Asp Gln Glu Leu Asp Ile Asn Arg Leu
835 840 845
Ser Asp Tyr Asp Val Asp His Ile Val Pro Gln Ser Phe Leu Lys Asp
850 855 860
Asp Ser Ile Asp Asn Lys Val Leu Thr Arg Ser Asp Lys Asn Arg Gly
865 870 875 880
Lys Ser Asp Asn Val Pro Ser Glu Glu Val Val Lys Lys Met Lys Asn
885 890 895
Tyr Trp Arg Gln Leu Leu Asn Ala Lys Leu Ile Thr Gln Arg Lys Phe
900 905 910
Asp Asn Leu Thr Lys Ala Glu Arg Gly Gly Leu Ser Glu Leu Asp Lys
915 920 925
Ala Gly Phe Ile Lys Arg Gln Leu Val Glu Thr Arg Gln Ile Thr Lys
930 935 940
His Val Ala Gln Ile Leu Asp Ser Arg Met Asn Thr Lys Tyr Asp Glu
945 950 955 960
Asn Asp Lys Leu Ile Arg Glu Val Lys Val Ile Thr Leu Lys Ser Lys
965 970 975
Leu Val Ser Asp Phe Arg Lys Asp Phe Gln Phe Tyr Lys Val Arg Glu
980 985 990
Ile Asn Asn Tyr His His Ala His Asp Ala Tyr Leu Asn Ala Val Val
995 1000 1005
Gly Thr Ala Leu Ile Lys Lys Tyr Pro Lys Leu Glu Ser Glu Phe Val
1010 1015 1020
Tyr Gly Asp Tyr Lys Val Tyr Asp Val Arg Lys Met Ile Ala Lys Ser
1025 1030 1035 1040
Glu Gln Glu Ile Gly Lys Ala Thr Ala Lys Tyr Phe Phe Tyr Ser Asn
1045 1050 1055
Ile Met Asn Phe Phe Lys Thr Glu Ile Thr Leu Ala Asn Gly Glu Ile
1060 1065 1070
Arg Lys Arg Pro Leu Ile Glu Thr Asn Gly Glu Thr Gly Glu Ile Val
1075 1080 1085
Trp Asp Lys Gly Arg Asp Phe Ala Thr Val Arg Lys Val Leu Ser Met
1090 1095 1100
Pro Gln Val Asn Ile Val Lys Lys Thr Glu Val Gln Thr Gly Gly Phe
1105 1110 1115 1120
Ser Lys Glu Ser Ile Leu Pro Lys Arg Asn Ser Asp Lys Leu Ile Ala
1125 1130 1135
Arg Lys Lys Asp Trp Asp Pro Lys Lys Tyr Gly Gly Phe Asp Ser Pro
1140 1145 1150
Thr Val Ala Tyr Ser Val Leu Val Val Ala Lys Val Glu Lys Gly Lys
1155 1160 1165
Ser Lys Lys Leu Lys Ser Val Lys Glu Leu Leu Gly Ile Thr Ile Met
1170 1175 1180
Glu Arg Ser Ser Phe Glu Lys Asn Pro Ile Asp Phe Leu Glu Ala Lys
1185 1190 1195 1200
Gly Tyr Lys Glu Val Lys Lys Asp Leu Ile Ile Lys Leu Pro Lys Tyr
1205 1210 1215
Ser Leu Phe Glu Leu Glu Asn Gly Arg Lys Arg Met Leu Ala Ser Ala
1220 1225 1230
Gly Glu Leu Gln Lys Gly Asn Glu Leu Ala Leu Pro Ser Lys Tyr Val
1235 1240 1245
Asn Phe Leu Tyr Leu Ala Ser His Tyr Glu Lys Leu Lys Gly Ser Pro
1250 1255 1260
Glu Asp Asn Glu Gln Lys Gln Leu Phe Val Glu Gln His Lys His Tyr
1265 1270 1275 1280
Leu Asp Glu Ile Ile Glu Gln Ile Ser Glu Phe Ser Lys Arg Val Ile
1285 1290 1295
Leu Ala Asp Ala Asn Leu Asp Lys Val Leu Ser Ala Tyr Asn Lys His
1300 1305 1310
Arg Asp Lys Pro Ile Arg Glu Gln Ala Glu Asn Ile Ile His Leu Phe
1315 1320 1325
Thr Leu Thr Asn Leu Gly Ala Pro Ala Ala Phe Lys Tyr Phe Asp Thr
1330 1335 1340
Thr Ile Asp Arg Lys Arg Tyr Thr Ser Thr Lys Glu Val Leu Asp Ala
1345 1350 1355 1360
Thr Leu Ile His Gln Ser Ile Thr Gly Leu Tyr Glu Thr Arg Ile Asp
1365 1370 1375
Leu Ser Gln Leu Gly Gly Asp Lys Arg Pro Ala Ala Thr Lys Lys Ala
1380 1385 1390
Gly Gln Ala Lys Lys Lys Lys
1395
<210> 4
<211> 225
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 4
ggcttgtcgg actcttcgct attacgccag ctggcgaagg gggatgtgct gcaaggcgat 60
taagttgggt aacgccaggg ttttcccagt cacgacgtta ggaaattaat acgactcact 120
ataggagagc acagtcagcc tggcggtttt agagctagaa atagcaagtt aaaataaggc 180
tagtccgtta tcaacttgaa aaagtggcac cgagtcggtg ctttt 225
<210> 5
<211> 225
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 5
ggcttgtcgg actcttcgct attacgccag ctggcgaagg gggatgtgct gcaaggcgat 60
taagttgggt aacgccaggg ttttcccagt cacgacgtta ggaaattaat acgactcact 120
ataggcttcc agaattggat ctccggtttt agagctagaa atagcaagtt aaaataaggc 180
tagtccgtta tcaacttgaa aaagtggcac cgagtcggtg ctttt 225
<210> 6
<211> 102
<212> RNA
<213> Artificial Sequence (Artificial Sequence)
<400> 6
ggagagcaca gucagccugg cgguuuuaga gcuagaaaua gcaaguuaaa auaaggcuag 60
uccguuauca acuugaaaaa guggcaccga gucggugcuu uu 102
<210> 7
<211> 102
<212> RNA
<213> Artificial Sequence (Artificial Sequence)
<400> 7
ggcuuccaga auuggaucuc cgguuuuaga gcuagaaaua gcaaguuaaa auaaggcuag 60
uccguuauca acuugaaaaa guggcaccga gucggugcuu uu 102
<210> 8
<211> 242
<212> PRT
<213> Sus scrofa
<400> 8
Met Gln Leu Phe Pro Arg Ser Leu Ser Cys Gly Leu Lys Gly Gln Ala
1 5 10 15
Glu Asp Leu Glu Lys Glu Val Ala Leu Ala Phe Gly Leu Ala Leu Ala
20 25 30
Thr Leu Val Gln Ala Val Gly His Ile Ser Gly Ala His Val Asn Pro
35 40 45
Ala Val Thr Phe Ala Phe Leu Val Gly Ser Gln Met Ser Leu Phe Arg
50 55 60
Ala Phe Cys Tyr Met Ala Ala Gln Leu Leu Gly Ala Val Ala Gly Ala
65 70 75 80
Ala Val Leu Tyr Ser Val Thr Pro Pro Ala Val Arg Gly Asn Leu Ala
85 90 95
Leu Asn Thr Leu His Pro Gly Val Ser Val Gly Gln Ala Thr Ile Val
100 105 110
Glu Ile Phe Leu Thr Leu Gln Phe Val Leu Cys Ile Phe Ala Thr Tyr
115 120 125
Asp Glu Arg Arg Asn Gly Arg Leu Gly Ser Val Ala Leu Ala Val Gly
130 135 140
Phe Ser Leu Thr Leu Gly His Leu Phe Gly Met Tyr Tyr Thr Gly Ala
145 150 155 160
Gly Met Asn Pro Ala Arg Ser Phe Ala Pro Ala Ile Leu Thr Arg Ser
165 170 175
Phe Thr Asn His Trp Val Tyr Trp Val Gly Pro Ile Ile Gly Ala Gly
180 185 190
Leu Gly Ser Leu Leu Tyr Asp Phe Leu Leu Phe Pro Arg Leu Lys Ser
195 200 205
Val Ser Glu Arg Leu Ser Ile Leu Lys Gly Ala Arg Pro Ser Asp Ser
210 215 220
Asn Gly Gln Pro Glu Gly Thr Gly Glu Pro Val Glu Leu Lys Thr Gln
225 230 235 240
Ala Leu
<210> 9
<211> 1031
<212> DNA
<213> Sus scrofa
<400> 9
actagccctg gccctacccc ccccaacccc gcctcacacc catggctctg ctcacctccc 60
atttgagaag ggaggggaaa atgcagttga tttgcattta gaaaatgatc atgggcccgg 120
ccctctgcag cagtgaaggg gttaagaggc tgggccagcc acctcagcct gcccctccca 180
gggattaaga gtcctctata aaggggactg ttcatccaga tcgcgccagg ggggtatcag 240
ggacccaggc atcgtgccca tcccccctgc catgtgggaa ctgcggtcag cctccttctg 300
gagggccata tttgctgagt tctttgccac cctcttctat gtcttctttg ggctgggggc 360
ttcactgcgt tggaccccgg gaccacttca tgtcttacag gtggctctgg cctttggcct 420
ggccctggct accctggtgc aggctgtggg ccacatcagc ggagcccatg tcaaccccgc 480
cgtcactttc gccttcctcg tgggctccca gatgtctctg ttccgtgcct tctgctacat 540
ggcagcccag ctcctgggag cagtggctgg agccgctgtt ctgtacagtg ttaccccgcc 600
tgccgtccga ggaaacctag cacttaatac ggtaatggtt ggccaattgg ggcgagggga 660
acccgaagct cccacttcct gcctgtgcag gtggatcagt tccccagggg tctgggatat 720
tgtatgtgag tgtgtgtttc aaggtgggaa gaatcaacag gtgctctgga gaggtaaaga 780
agtcatagag ccctggaact gagttcaggt cccagcttcc ctcctaacac cttgcaggtt 840
cttttttttt tttttttttt ttttttttta ggaccacatc tgcagcatat ggaggttccc 900
aggctagggt tcaaattgga gctgcatctg aaggccccag ccacagcaat gccagatcct 960
taaaccactg agtgggacca gggattgatt gaacccgcat cctcatggat actagttggg 1020
ttcatttctg c 1031
<210> 10
<211> 100
<212> RNA
<213> Artificial Sequence (Artificial Sequence)
<400> 10
gguaacacug uacagaacag guuuuagagc uagaaauagc aaguuaaaau aaggcuaguc 60
cguuaucaac uugaaaaagu ggcaccgagu cggugcuuuu 100
<210> 11
<211> 100
<212> RNA
<213> Artificial Sequence (Artificial Sequence)
<400> 11
ggaaggcgaa agugacggcg guuuuagagc uagaaauagc aaguuaaaau aaggcuaguc 60
cguuaucaac uugaaaaagu ggcaccgagu cggugcuuuu 100
<210> 12
<211> 100
<212> RNA
<213> Artificial Sequence (Artificial Sequence)
<400> 12
gagacaucug ggagcccacg guuuuagagc uagaaauagc aaguuaaaau aaggcuaguc 60
cguuaucaac uugaaaaagu ggcaccgagu cggugcuuuu 100
<210> 13
<211> 100
<212> RNA
<213> Artificial Sequence (Artificial Sequence)
<400> 13
cugccaugua gcagaaggca guuuuagagc uagaaauagc aaguuaaaau aaggcuaguc 60
cguuaucaac uugaaaaagu ggcaccgagu cggugcuuuu 100
<210> 14
<211> 100
<212> RNA
<213> Artificial Sequence (Artificial Sequence)
<400> 14
agugacggcg ggguugacau guuuuagagc uagaaauagc aaguuaaaau aaggcuaguc 60
cguuaucaac uugaaaaagu ggcaccgagu cggugcuuuu 100
<210> 15
<211> 100
<212> RNA
<213> Artificial Sequence (Artificial Sequence)
<400> 15
caucugggag cccacgagga guuuuagagc uagaaauagc aaguuaaaau aaggcuaguc 60
cguuaucaac uugaaaaagu ggcaccgagu cggugcuuuu 100
<210> 16
<211> 225
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 16
ggcttgtcgg actcttcgct attacgccag ctggcgaagg gggatgtgct gcaaggcgat 60
taagttgggt aacgccaggg ttttcccagt cacgacgtta ggaaattaat acgactcact 120
ataggggaag gcgaaagtga cggcggtttt agagctagaa atagcaagtt aaaataaggc 180
tagtccgtta tcaacttgaa aaagtggcac cgagtcggtg ctttt 225
<210> 17
<211> 225
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 17
ggcttgtcgg actcttcgct attacgccag ctggcgaagg gggatgtgct gcaaggcgat 60
taagttgggt aacgccaggg ttttcccagt cacgacgtta ggaaattaat acgactcact 120
atagggagac atctgggagc ccacggtttt agagctagaa atagcaagtt aaaataaggc 180
tagtccgtta tcaacttgaa aaagtggcac cgagtcggtg ctttt 225
<210> 18
<211> 102
<212> RNA
<213> Artificial Sequence (Artificial Sequence)
<400> 18
ggggaaggcg aaagugacgg cgguuuuaga gcuagaaaua gcaaguuaaa auaaggcuag 60
uccguuauca acuugaaaaa guggcaccga gucggugcuu uu 102
<210> 19
<211> 102
<212> RNA
<213> Artificial Sequence (Artificial Sequence)
<400> 19
gggagacauc ugggagccca cgguuuuaga gcuagaaaua gcaaguuaaa auaaggcuag 60
uccguuauca acuugaaaaa guggcaccga gucggugcuu uu 102

Claims (14)

  1. The application of MIP-gRNA2, MIP-gRNA3 and NCN protein in the preparation of a kit;
    the MIP-gRNA2 is sgRNA, and the binding region of the target sequence is shown in SEQ ID NO:18, nucleotides 3 to 22; the MIP-gRNA3 is sgRNA, and the binding region of the target sequence is shown in SEQ ID NO:19 at nucleotides 3-22; the NCN protein is a Cas9 protein or a fusion protein with a Cas9 protein;
    the application of the kit is as follows (a), (b) or (c): (a) preparing a recombinant cell; (b) preparing cataract model pig; (c) Preparing a cataract cell model or a cataract tissue model or a cataract organ model.
  2. The application of MIP-gRNA2, MIP-gRNA3 and PRONCN proteins in the preparation of a kit;
    the MIP-gRNA2 is the MIP-gRNA2 described in claim 1; MIP-gRNA3 is the MIP-gRNA3 described in claim 1;
    the PRONCN protein sequentially comprises the following elements from upstream to downstream: signal peptide, molecular chaperone protein, protein tag, protease enzyme cutting site, nuclear localization signal, cas9 protein and nuclear localization signal;
    the application of the kit is as follows (a), (b) or (c): (a) preparing a recombinant cell; (b) preparing cataract model pig; (c) Preparing a cataract cell model or a cataract tissue model or a cataract organ model.
  3. 3, application of MIP-gRNA2, MIP-gRNA3 and the very heterogeneous particles in preparation of the kit;
    MIP-gRNA2 is the MIP-gRNA2 described in claim 1; MIP-gRNA3 is the MIP-gRNA3 described in claim 1;
    the specific plasmid sequentially comprises the following elements from upstream to downstream: a promoter, an operator, a ribosome binding site, a PRONCN protein coding gene and a terminator; the PRONCN protein sequentially comprises the following elements from upstream to downstream: signal peptide, molecular chaperone protein, protein tag, protease enzyme cutting site, nuclear localization signal, cas9 protein and nuclear localization signal;
    the application of the kit is as follows (a), (b) or (c): (a) preparing a recombinant cell; (b) preparing cataract model pig; (c) Preparing a cataract cell model or a cataract tissue model or a cataract organ model.
  4. 4. A method of making a recombinant cell comprising the steps of: carrying out cotransfection on the MIP-gRNA2, the MIP-gRNA3 and the NCN protein to a pig cell to obtain a recombinant cell; MIP-gRNA2 is the MIP-gRNA2 described in claim 1; MIP-gRNA3 is the MIP-gRNA3 described in claim 1; the NCN protein is the NCN protein according to claim 1.
  5. 5. The method of claim 4, wherein: the proportions of the pig cells, the MIP-gRNA2, the MIP-gRNA3 and the NCN protein are as follows in sequence: 10 ten thousand porcine cells: 0.8-1.2 μ g MIP-gRNA2:0.8-1.2 μ g MIP-gRNA3: 3-5. Mu.g NCN protein.
  6. 6. A kit comprising MIP-gRNA2, MIP-gRNA3, and NCN protein;
    MIP-gRNA2 is the MIP-gRNA2 described in claim 1; MIP-gRNA3 is the MIP-gRNA3 described in claim 1; the NCN protein is the NCN protein described in claim 1;
    the application of the kit is as follows (a), (b) or (c): (a) preparing a recombinant cell; (b) preparing cataract model pig; (c) Preparing a cataract cell model or a cataract tissue model or a cataract organ model.
  7. 7. A kit comprising MIP-gRNA2, MIP-gRNA3, and PRONCN protein;
    MIP-gRNA2 is the MIP-gRNA2 described in claim 1; MIP-gRNA3 is the MIP-gRNA3 described in claim 1; the PRONCN protein is the PRONCN protein of claim 2;
    the application of the kit is as follows (a), (b) or (c): (a) preparing a recombinant cell; (b) preparing cataract model pig; (c) Preparing a cataract cell model or a cataract tissue model or a cataract organ model.
  8. 8. A kit, comprising MIP-gRNA2, MIP-gRNA3 and specific plasmids;
    MIP-gRNA2 is the MIP-gRNA2 described in claim 1; MIP-gRNA3 is the MIP-gRNA3 described in claim 1; the specific plasmid is the specific plasmid described in claim 3;
    the application of the kit is as follows (a), (b) or (c): (a) preparing a recombinant cell; (b) preparing cataract model pig; (c) Preparing a cataract cell model or a cataract tissue model or a cataract organ model.
  9. 9. The use according to claim 1 or the method according to claim 4 or 5 or the kit according to claim 6, characterized in that: the NCN protein is shown as SEQ ID NO:3, respectively.
  10. 10. The use or method or kit as claimed in claim 9, wherein:
    the preparation method of the NCN protein comprises the following steps:
    (1) Introducing the plasmid pKG-GE4 into escherichia coli BL21 (DE 3) to obtain recombinant bacteria;
    (2) Culturing the recombinant strain by adopting a liquid culture medium at 30 ℃, adding IPTG (isopropyl-beta-thiogalactoside) and carrying out induced culture at 25 ℃, and then collecting thalli;
    (3) Crushing the collected thalli, and collecting a crude protein solution;
    (4) Purification of the crude protein solution with His by affinity chromatography 6 A fusion protein of the tag;
    (5) By means of a compound having His 6 Tagged enterokinase cleavage with His 6 The tagged fusion protein was then removed with His using Ni-NTA resin 6 A tagged protein, resulting in a purified NCN protein;
    plasmid pKG-GE4 has the sequence SEQ ID NO:1, nucleotide 5209-9852.
  11. 11. Recombinant cells produced by the method of claim 4 or 5 or 9 or 10.
  12. 12. Use of the recombinant cell of claim 11 for the preparation of cataract-model pigs.
  13. 13. Porcine tissue, porcine organ or porcine cells of a cataract-model pig prepared using the recombinant cells of claim 11.
  14. 14. The recombinant cell of claim 11, the porcine tissue of claim 13, the porcine organ of claim 13, the porcine cell of claim 13, or the cataract model pig prepared by using the recombinant cell of claim 11, wherein the recombinant cell is (d 1) or (d 2) or (d 3) or (d 4):
    (d1) Screening the medicine for treating cataract;
    (d2) Evaluating the drug effect of the cataract drug;
    (d3) Evaluating the curative effect of gene therapy and/or cell therapy of cataract;
    (d4) The pathogenesis of cataracts is studied.
CN202110923993.XA 2021-08-12 2021-08-12 Gene editing system for constructing MIP gene mutation cataract disease model pig nuclear transplantation donor cell and application thereof Pending CN115232815A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110923993.XA CN115232815A (en) 2021-08-12 2021-08-12 Gene editing system for constructing MIP gene mutation cataract disease model pig nuclear transplantation donor cell and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202110923993.XA CN115232815A (en) 2021-08-12 2021-08-12 Gene editing system for constructing MIP gene mutation cataract disease model pig nuclear transplantation donor cell and application thereof

Publications (1)

Publication Number Publication Date
CN115232815A true CN115232815A (en) 2022-10-25

Family

ID=83666382

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110923993.XA Pending CN115232815A (en) 2021-08-12 2021-08-12 Gene editing system for constructing MIP gene mutation cataract disease model pig nuclear transplantation donor cell and application thereof

Country Status (1)

Country Link
CN (1) CN115232815A (en)

Similar Documents

Publication Publication Date Title
KR101307880B1 (en) Recombinant expression of multiprotein complexes using polygenes
CN110923183A (en) Construction method of lanosterol-producing escherichia coli strain
CN113278061B (en) Method for preparing cable Ma Lutai by biochemical method
CN112553176B (en) Glutamine transaminase with improved thermal stability
CN115247173A (en) Gene editing system for constructing TMPRSS6 gene mutant iron deficiency anemia pig nuclear transplantation donor cells and application thereof
CN115232817A (en) Gene editing system for constructing three-gene combined mutant miniature pig nuclear transplantation donor cells and application thereof
CN115161335B (en) Gene editing system for constructing ALS model pig nuclear transfer donor cells with TARDBP gene mutation and application of gene editing system
CN115232815A (en) Gene editing system for constructing MIP gene mutation cataract disease model pig nuclear transplantation donor cell and application thereof
CN115232814A (en) Method and system for constructing congenital cataract disease model pig nuclear transplantation donor cells with CRYBB2 gene mutation
CN115232836A (en) Gene editing system for constructing congenital cataract model pig nuclear transplantation donor cell with CRYGC gene mutation and application thereof
CN115232818A (en) Gene editing system for constructing congenital myasthenia model pig nuclear transplantation donor cells with DOK7 gene mutation and application thereof
CN115232816A (en) CRISPR system for constructing cataract model pig nuclear transplantation donor cells with YAP1 gene mutation and application thereof
CN115247175A (en) Gene editing system for constructing epigenetic dysregulation model pig nuclear transplantation donor cell of SETDB1 gene mutation and application thereof
CN115232834A (en) Gene editing system for constructing nuclear transplantation donor cells of OCA-1A albinism model pigs and application thereof
CN115232794A (en) Gene editing system and application thereof in construction of OCA-1B albinism model pig nuclear transplantation donor cells
CN115232796A (en) Gene editing system for constructing central precocity model pig nuclear transplantation donor cells with MKRN3 gene mutation and application thereof
CN115247153A (en) Gene editing system for constructing diabetes model pig nuclear transplantation donor cells with HNF1A gene mutation and application thereof
CN115247191A (en) Gene editing system and application thereof in construction of double-gene-mutation nevus basal cell carcinoma syndrome pig nuclear transplantation donor cell
CN115232812A (en) Method for constructing nuclear transplantation donor cells of MRAP2 gene mutation severe early obesity model pigs
CN115232793A (en) Gene editing system for constructing ALS model pig nuclear transplantation donor cells with SOD1 gene mutation and application thereof
CN115232813A (en) Gene editing system for constructing von willebrand model pig nuclear transplantation donor cells with vWF gene mutation and application of gene editing system
CN115247164A (en) Gene editing system for constructing adenomatous polyposis model pig and colorectal cancer model pig and application thereof
CN115247174A (en) Gene editing system for constructing congenital gamma globulin deficiency model pig nuclear transplantation donor cell and application thereof
CN115232811A (en) Method for constructing HBB gene mutant sickle cell anemia model pig nuclear transplantation donor cell and application
CN115247163A (en) Gene editing system for constructing stomach cancer model pig nuclear transplantation donor cell with GP130 gene mutation and application thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination